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ABSTRACT

The unique population structure of dog breeds, arising from their domestication
from gray wolves and subsequent breed formation, and the similarity of their inherited
diseases to human disorders make them an ideal comparative genetics model. Herein the
genetic basis of three canine muscle diseases, each a model for human disease, is
investigated using genome-wide approaches. Nemaline rod myopathy (NM) is one of the
most common congenital myopathies in people and is characterized by rod bodies in the
muscle fibers, muscle weakness, and reduced muscle tone. We characterized the first
large animal model of autosomal recessive NM in a family of American bulldogs and,
through a combination of genome-wide SNP profiling and whole exome sequencing,
identified a nonsense mutation in NEB.
Limb girdle muscular dystrophy (LGMD) affects the hip and shoulder muscles
and may cause respiratory and cardiac muscle degeneration. We determined that a
muscular dystrophy in a family of Boston terriers is a sarcoglycanopathy, a type of
LGMD caused by mutations in one of six sarcoglycan genes, and identified a 2 bp
deletion in SGCD through direct whole exome sequencing. Further, an unrelated Boston
terrier having LGMD harbors a 19.4 kb deletion, omitting exons 7 and 8 of SGCD. The
NEB and SGCD mutations are present only in the affected families.
Juvenile dermatomyositis (JDM) is an autoimmune disease with a complex mode
of inheritance and an environmental trigger, affecting children ages 2 to 17. In dogs,
dermatomyositis (DMS) affects collies and Shetland sheepdogs and causes skin lesions
and muscle weakness. We conducted genome-wide association studies in both breeds and
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identified linkage disequilibrium with SNPs on chromosomes 10 and 31. Through whole
genome and transcriptome sequencing, we found mutations in two novel genes, PAN2
(chr10) and MAP3K7CL (chr31). Additionally, we identified an association with a
haplotype of the major histocompatibility complex class II genes on chromosome 12,
alleles of which are also associated with JDM. When variants at all three loci are
considered together, genotypes confer low, moderate, or high risk for DMS, with
moderate- and high-risk genotypes explaining 93% of cases.
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CHAPTER ONE
INTRODUCTION
Dog domestication
The earliest domesticated species, dogs (Canis lupus familiaris) descended from
one or more populations of gray wolves 11,000 to 35,000 years ago alongside huntergatherer societies [1]. Putative domestication origins include Europe, East Asia, and the
High Arctic. Changes in brain function, behavior, pigmentation, and diet and metabolism
have been implicated in early dog domestication [2-6].
While previous studies have compared modern dogs to gray wolves to identify
domestication genes, a recent study including village dogs, gray wolves, and three
ancient dogs identified selective sweeps containing genes with roles in neural crest
development and the minor spliceosome [7]. These genes may explain traits associated
with the “domestication syndrome” that is characteristic of mammalian domesticates and
includes floppy ears; depigmentation; and decreased body, skull, and jaw size [7,8].
Methylation patterns also appear to have been under selection during early domestication.
Janowitz Koch et al. [9] identified hypermethylation of transposons in dogs compared to
wolves, and suggest that transposons underwent expansion in dogs followed by
epigenetic silencing. Furthermore, Banlaki et al. [10] found evidence for differential
methylation between dogs and wolves specifically in the promoter regions of genes
related to behavior and cognitive function. Taken together, these studies suggest that
domestication phenotypes may be attributed to far-reaching, regulatory mechanisms
rather than wide-spread coding variants.
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After the first stage of domestication from wolves, with the emergence of
agriculture and a more sedentary human lifestyle, dogs began to appear in a range of
body sizes and became morphologically distinct from wolves [1,11]. Archaeological
evidence suggests that dogs were bred to pull sleds around 9000 ya in Siberia, possibly as
early as 15,000 ya; this is the earliest evidence of selective breeding for a job [12]. More
recently, dogs were bred for retrieving, hunting, defense, speed, and companionship;
modern breed formation during the Victorian era included artificial selection for novelty
or “fancy” [13,14]. This final stage of domestication yielded the majority of dog diversity
[1,15], and today, there is more phenotype variability among dogs than in the entire
carnivore order [1].

Dogs as a model
There are over 400 breeds of dog [16], and they are afflicted with approximately
360 simple and complex naturally-occurring diseases analogous to human disease [17].
Dogs are superior disease models to rodents in a number of ways. As pets, dogs receive
excellent medical care and typically have extensive health records and even family
histories. Biological samples can be obtained from the pet population for identifying
disease alleles, eliminating expenses associated with maintaining laboratory animals. As
companion animals, dogs share their owners’ environment and thus are more likely than
rodent models to be exposed to toxins and other environmental agents playing a role in
complex disease [18].

2

Dogs have organ sizes similar to humans and may even be more similar
genetically [17], which makes them particularly advantageous for gene therapy and drug
trials. While rodent models are useful for developing gene therapies, scaling up the
injections to human treatment poses a problem because host body weight, metabolic rate,
and response are all factors that may not translate from a rodent model to humans [19].
Further, negligible contamination levels at a small-scale could be amplified and cause an
immune response when the scale is increased for human trials [20]. Dog models are an
ideal intermediate system to address these issues because of their more comparable size
to humans [19], and dog models for hemophilia and inherited bleeding disorders have
been successfully used to determine safe doses and prevent immune responses in trials
that have translated to human treatment [21].
Dogs underwent two population bottlenecks: domestication from wolves and
breed formation. The latter resulted in founder effects where a small number of
individuals formed the basis for a breed, popular sire effects where studs who excel in
competitions are selected to sire a disproportionately high number of puppies, and within
breed population bottlenecks due to changes in breed standards or events like the World
Wars, which led to near extinction of some breeds. These factors caused high genetic
homogeneity and long stretches of linkage disequilibrium (LD) within breeds, on average
extending 1 Mb, 100-fold greater than LD in humans [22-24]. Thus, fewer markers and
fewer individuals are necessary to detect disease loci in dogs, tens of thousands of
markers compared to millions needed in human studies [22,23]. However, the long LD
can result in broad associated candidate intervals containing many genes for investigating
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mutations. Because across-breed LD is comparable to what is observed in humans (~10
kb) [22,23], fine-mapping studies may be successful using multiple breeds with the same
phenotype to narrow these critical intervals.
A consequence of selective breeding practices is that deleterious alleles become
overrepresented in certain breeds so that about half of heritable diseases are breedspecific, making breeds similar to geographically isolated human populations [25]. These
alleles are passed on identical by descent within breeds and, thus, approximately twothirds of hereditary diseases in dogs are autosomal recessive [26]. For complex diseases
in dogs, reduced locus heterogeneity within breeds is expected compared to human
populations. It is likely that in dogs, a small number of genes with large effect drive
complex diseases that in humans are governed by many loci of small effect [16]. This
facilitates identification of associated genes; dogs may even have a recessive form of a
human complex disease. Safra et al. [27] identified a novel gene in Weimereiners with an
autosomal recessive neural tube defects, a disorder with complex inheritance patterns in
humans. The gene was then found to be involved in human cases [27]. Complex disorders
may also be studied across affected breeds to find multiple genes involved. For example,
epilepsy manifests in different ways and certain breeds are affected with different types
[16].

Identification of disease variants in dogs
The canine genome comprises 2.8 billion base pairs packaged into 38 acrocentric
autosomes. In 2004, the dog reference genome was sequenced to 7.8x coverage in a
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female Boxer, selected because she had low heterozygosity and provided full coverage of
the X chromosome. A SNP map based on sequences from nine additional breeds and the
1.5x genome of a standard poodle was also made publicly available [23,28]. Since the
release of the reference, single nucleotide polymorphism (SNP) arrays have been
developed for genome-wide association studies (GWAS) [29]. GWAS generate
genotypes for SNPs distributed throughout the genome and compare allele frequencies
between unrelated affected and healthy individuals. SNP markers proximal to the
causative mutation will be in LD, yielding an associated region. Development of the
Affymetrix 50K platinum panel and Illumina 22K SNP arrays enabled successful GWAS
[30-34], including identification of a novel ichthyosis gene in Golden retrievers, which
led investigators to mutations in the same gene in human cases [35].
Today an Illumina CanineHD Bead Chip is available containing over 173,000
SNPs, which within breeds yields between 80,000 and 120,000 informative markers,
sufficient coverage to identify loci associated with simple Mendelian disorders and some
complex diseases [29]. With this array, simple disorders can be mapped with very small
numbers of cases. For example, the Safra et al. [27] study of an autosomal recessive
neural tube defect in Weimereiners used only 4 affected dogs in the GWAS.
After identifying an associated region through GWAS, the best candidate gene(s)
within the critical interval is typically selected for Sanger sequencing to identify the
causative mutation [36-42]. This approach can be costly and time intensive, particularly if
the candidate genes are too numerous or too large. Recently, next generation sequencing
(NGS), or high through-put sequencing, technologies have been developed that perform
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parallel sequencing of millions of DNA fragments; the sequences are then aligned to a
reference genome. NGS may be used to sequence the entire (whole genome resequencing
– WGS) or a portion of the genome (targeted-resequencing), only the exons and
sometimes introns and regulatory regions (whole exome sequencing – WES), or the
transcriptome (RNAsequencing) of multiple individuals concurrently. Targeted and WGS
technologies were first used in dog studies in 2011-2012, followed by the less-expensive
WES in 2013, and the cost of NGS continues to decline [29]. NGS technologies now
allow for rapid variant detection and screening following GWAS [43-55].
Recently, WGS has been utilized to identify mutations without prior mapping.
When there are several known candidate genes for a recessive disease, WGS of a single
case has been effective for simultaneously investigating all candidates and identifying a
deleterious variant [56-58]. WGS has also been employed in family trio studies to filter
variants for recessive mutations in the affected individual and obligate carrier parents
without positional or functional candidate genes [59]. Other studies have identified
homozygous mutations underlying recessive disease by scanning the entire genome of a
single case and ruling out all variants present in the genomes of dogs of other breeds until
a unique, deleterious variant is identified [60-61]. Bauer et al. [62] even identified a
dominant de novo mutation this way for a German shepherd with ichthyosis.
Whole exome sequencing (WES) kits provide a more cost-effective alternative to
WGS in these simple Mendelian disorders that are likely to be caused by coding
mutations. A handful of studies have already used this technique alone or with mapping
to identify mutations in progressive retinal atrophy [63], glaucoma [64], and neuroaxonal
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dystrophy [65]. Genotyping by WES was also used to conduct a GWAS for glaucoma in
Petit Basset Griffon Vendéens [66]. Variant calling and filtering for minor allele
frequency less than 5% in 12 cases and 12 controls yielded 61,977 SNPs, and allele
frequency analysis revealed an association on chromosome 3. Subsequent WGS of a
single case detected an inversion in ADAMTS17.
In contrast to simple recessive or dominant diseases, complex polygenic traits in
dogs may require denser SNP arrays than the Illumina 170k and more individuals to
detect associations in GWAS. Hayward et al. [67] conducted GWAS with 4,200 dogs and
180,000 SNPs to identify across-breed associations with multiple complex diseases,
including hip and elbow dysplasia and morphological traits like fur length and shedding.
The authors suggest that increased SNP density will still be necessary for complex
diseases and were unable to detect significant associations for several other disorders they
investigated like lymphoma, mast cell tumor, and mitral valve degeneration.
Associations with multigenic disease have been identified using fewer than the
100 cases and 100 controls initially proposed by Lindblad-Toh et al. [23]. Karyadi et al.
[68] mapped squamous cell carcinoma of the digit (SCCD) using 31 case and 34 control
standard poodles to a region on chromosome 15. They narrowed the critical interval,
where all affected dogs possessed at least one copy of the risk haplotype, from 813 kb to
145 kb by investigating these SNPs in cases from two other breeds also affected with
SCCD, Briards and Giant Schnauzers, and ultimately found a strongly associated copy
number variant in KITLG [68]. Across-breed fine mapping approaches can be highly
effective in the case of complex disease because the LD is much narrower compared to
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within breeds. SCCD disproportionately affects dogs with dark coats, so after the initial
GWAS with only dark-coated standard poodles, the authors performed a second GWAS
comparing 24 control dark-coated to 24 light-coated control poodles. Because no
significant associations outside of MCR1, which controls coat color and is a known skin
cancer susceptibility locus, were detected, the authors propose that a compensatory
mutation in this gene in light-coated dogs likely confers protection from SCCD.
Multibreed GWAS, potentially with denser SNP arrays, followed by whole
genome and/or transcriptome sequencing will likely be necessary to detect variants
underlying complex disease in dogs, especially since many will involve regulatory
mutations rather than coding changes.

Canine myopathies
Myopathy refers to any disease affecting the skeletal muscle and causing muscle
weakness, without disorders of innervation or the neuromuscular junction. Two examples
of canine myopathies and their utility as genetic models are Duchenne muscular
dystrophy (DMD) and X-linked myotubular myopathy (XLMTM). DMD is characterized
by the absence of dystrophin, a protein essential for muscle cell stability. Mouse and
canine DMD (cDMD) models have been available for study for the last 30 years, but
cDMD is more clinically and histologically similar to DMD and can replicate human
immune response to gene therapy [19]. XLMTM was identified in a family of Labrador
retrievers [69] found to harbor a mutation in MTM1 [70], the same gene that causes
XLMTM in humans [71]. Affected dogs closely recapitulate the human symptoms [70],
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and gene therapy first developed in a mouse model was successfully refined in dogs to
correct muscle weakness [72]. In addition to muscular dystrophies and XLMTM, cases of
nemaline rod myopathy, central core-like myopathy, myofibrillar myopathy with desmin
storage, and centronuclear myopathy have been described in dogs [73]. Herein the
genetic basis of three canine myopathies is described.
Nemaline rod myopathy
Nemaline rod myopathy (NM) accounts for 17% of congenital myopathies in
humans and causes reduced muscle strength and tone, involving the neck, face, and
respiratory muscles [74]. NM is characterized by rod bodies in the skeletal muscle fiber
and is most often caused by mutations in 10 genes encoding proteins of the sarcomere
thin filament, which is essential for muscle contraction. The majority of cases are
attributed to dominant mutations in ACTA1 or recessive mutations in NEB [74]. ACTA1
encodes the primary component of the thin filament, actin, and NEB produces the giant
protein nebulin, which stabilizes actin and allows the thin filament to reach the
appropriate length [75]. The number of rod bodies in the muscle fiber is not correlated
with disease severity. Of the 10 genes known to cause NM [76], mouse and/or zebrafish
models exist for 5, including ACTA1 and NEB [77-88]; however, no large animal models
have been described. NM has been reported in Border collie and a Schipperke, but the
genetic basis is unknown [73]. Herein, the first molecularly characterized NM in dogs is
described.
Limb girdle muscular dystrophy
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Limb girdle muscular dystrophies (LGMD) are characterized by progressive
deterioration of the shoulder and hip muscles and may involve the heart and respiratory
muscles. Age of onset and severity are variable, and 31 genes have been implicated [89].
Autosomal recessive forms are most common with an incidence of 1 in 15,000 births
[90]. Four of the 23 recessive subtypes of LGMD are caused by mutations in any of the
four genes encoding subunits of the sarcoglycan complex and are termed
“sarcoglycanopathies” [89]. Sarcoglycans function in stabilizing the cell membrane of
muscle fibers. Mouse models exist for each form [91], and a spontaneous hamster model
is available for δ-sarcoglycanopathy [92,93]. Gene therapy trials are already underway in
humans for α-sarcoglycanopathy [94,95].
Sarcoglycanopathy has been reported in a Boston terrier, Cocker Spaniel, and
Chihuahua [73], but the cause is unknown in each case. Herein, the genetic basis of a
sarcoglycanopathy in two Boston terriers is described; this is the first molecularly
characterized large animal model of this disease.
Dermatomyositis
Juvenile dermatomyositis (JDM) is the most common inherited childhood
inflammatory myopathy [96]. JDM causes a rash on the bony prominences (e.g. across
the cheekbones, elbows, knees, back, and chest) [96]. Muscle weakness is common, and
affected children describe their muscles as achy and tender and may have difficulty rising
from a seated position or climbing stairs [97]. Like most autoimmune diseases in humans,
females are more often affected than males [98]. JDM is strongly associated with a
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haplotype of the human leukocyte antigen genes of the major histocompatibility complex;
however, other genetic factors of major effect are believed to be involved [99,100].
Canine dermatomyositis (DMS), a model for JDM, is an autoimmune
vasculopathy that causes alopecia and skin lesions on the bony prominences (e.g. the
face, ears, tail tip, and across the tops of the feet) [101-103]. Severe cases also involve the
muscles, which may result in an abnormal high-stepping gate, megaesophagus, and/or
aspiration pneumonia [101,103]. Decreased muscle tone may be evident in the head
musculature [101]. Clinical signs typically appear subsequent to an environmental trigger
such as viral infection or vaccination [104]. Lesions may wax and wane throughout a
dog’s lifetime and can be exacerbated by estrus or exposure to UV light [101,103]. Age
of onset is variable with most dogs developing clinical signs between seven weeks and
six months of age, but others developing signs in late adulthood [103,105]. This makes
the disease very difficult to eliminate from the two breeds almost exclusively diagnosed
with DMS: the collie and Shetland sheepdog.

The goal of this work is to identify mutations causing two simple recessive
diseases: NM in American bulldogs and LGMD in Boston terriers, and one complex
disease, DMS in collies and Shetland sheepdogs. In the case of NM, SNP arrays were
used to identify regions of the genome inherited in an autosomal recessive manner in a
nuclear family. Cross-referencing with known candidate genes resulted in two genes of
interest, and subsequent WES identified a nonsense mutation in NEB. Two mutations
underlying LGMD in independent Boston terrier families were identified in a known
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candidate gene via WES of the affected dogs and relatives. Finally, multi-breed GWAS,
WGS, and transcriptome sequencing were all employed to identify three polymorphisms
that in combination confer low, moderate, or high risk for DMS.
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Abstract
Nemaline myopathy (NM) is a congenital muscle disorder associated with muscle
weakness, hypotonia, and rod bodies in the skeletal muscle fibers. Mutations in 10 genes
have been implicated in human NM, but spontaneous cases in dogs have not been
genetically characterized. We identified a novel recessive myopathy in a family of linebred American bulldogs (ABDs); rod bodies in muscle biopsies established this as NM.
Using SNP profiles from the nuclear family, we evaluated inheritance patterns at
candidate loci and prioritized TNNT1 and NEB for further investigation. Whole exome
sequencing of the dam, two affected littermates, and an unaffected littermate revealed a
nonsense mutation in NEB (g.52734272 C>A, S8042X). Whole tissue gel electrophoresis
and western blots confirmed a lack of full-length NEB in affected tissues, suggesting
nonsense-mediated decay. The pathogenic variant was absent from 120 dogs of 24 other
breeds and 100 unrelated ABDs, suggesting that it occurred recently and may be private
to the family. This study presents the first molecularly characterized large animal model
of NM, which could provide new opportunities for therapeutic approaches.
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Introduction
One of the most common human congenital myopathies, accounting for 17% of
cases, nemaline myopathy (NM) is characterized by the presence of rod bodies in the
skeletal muscle fibers, muscle weakness, and hypotonia [1]. Proximal limb muscles,
facial muscles, and neck flexors are most frequently affected by muscle weakness, while
respiratory insufficiency is the primary cause of death [1]. NM is clinically
heterogeneous and is classified into six subtypes based on severity, pattern of muscle
weakness, and age of onset [2]. Ten genes have been implicated in NM: ACTA1, CFL2,
KBTBD13, KLHL40, KHL41, LMOD3, NEB, TNNT1, TPM2, and TPM3 [3]. These genes
encode proteins associated with the skeletal muscle sarcomere thin filament or Kelch
domain proteins [4].
While founder mutations have been reported in Ashkenazi Jewish (NEB) [5], Old
Order Amish (TNNT1) [6], and Turkish (TPM3) [7] populations, most NM cases involve
de novo mutations. Among cases explained at the genetic level, most are attributed to
recessive mutations in NEB (usually in compound heterozygosity) and dominant
mutations in ACTA1 [1]. It is often infeasible to identify de novo mutations through
Sanger sequencing due to numerous candidate genes and the prohibitive size of the NEB
transcript (~26 kb, 183 exons). In recent years, next generation sequencing technologies
that allow for simultaneous capture of candidate genes have expedited the genetic
characterization of individual NM cases [8-11].
Mouse models harboring mutations in ACTA1 [12-14], LMOD3 [15], KLHL40
[16], NEB [17-19], and TPM3 [20,21] are available for study of NM subtypes, but no

30

large animal models have been described. Dog models have been instrumental in
advancing therapeutic strategies for hereditary muscle disorders such as Duchenne
muscular dystrophy and myotubular myopathy [22,23]. While spontaneously occurring
forms of NM have been reported in a Border collie and a Schipperke, they were not
characterized at the molecular level [24]. Herein, we describe a novel NM in a family of
American bulldogs (ABDs) and determine the pathogenic variant through genome-wide
SNP profiling and whole exome sequencing (WES).

Materials & Methods
Animals
A five month old male ABD was evaluated at the University of Guelph
Veterinary Teaching Hospital for non-progressive generalized muscle weakness, exercise
intolerance, and tremors beginning at approximately two months of age. A female
littermate had similar clinical signs, while another female littermate was reported to be
clinically unaffected. Two other littermates could not be located. The sire and dam of the
litter were cousins, and there was no prior history of muscle disease in the family.
Samples from the family were collected for diagnostic procedures and submitted with
owner consent.

Histopathology and immunohistochemistry
Biopsies from the triceps, biceps femoris, and suprascapular muscles were
collected from both affected dogs under general inhalational anesthesia following
electrophysiological examination. The biopsy specimens were either snap frozen in
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isopentane (pre-cooled in liquid nitrogen) or immersion fixed in 2.5% glutaraldehyde for
electron microscopy. Sections (8 μm) were further processed using a standard panel of
histological and histochemical stains and reactions [25]. Similar staining and reactions
were performed on age-matched control muscles from the tissue archives of the
Comparative Neuromuscular Laboratory.

Electron Microscopy
Glutaraldehyde-fixed muscle specimens were post-fixed in 1% aqueous osmium
tetroxide prior to dehydration and embedding in araldite resin. Thick sections (1 µm)
were stained with toluidine blue-basic fuchsin prior to light microscopic examinations,
while thin sections (60-90 nm) were stained with uranyl acetate and lead citrate prior to
examination in a Zeiss 10 electron microscope.

DNA preparation
DNA was extracted from muscles of both affected dogs and blood from the sire,
dam, and unaffected littermate using the DNeasy extraction kit (Qiagen, Hilden,
Germany). Whole blood samples from ABDs recruited for an unrelated study were
obtained as controls [26]. DNA was isolated following the Gentra PureGene protocol
(Qiagen). Genomic DNAs from purebred dogs of other breeds were available from our
private DNA bank at Clemson University.

32

Illumina SNP arrays
To date, 10 genes have been identified in human cases of NM; their canine
counterparts lie on 10 different chromosomes. To investigate inheritance patterns at each
gene, SNP profiles were generated for the nuclear family using the Illumina CanineHD
BeadChip, containing 173,662 SNPs (Illumina, San Diego, CA, USA). Genotypes at
polymorphic SNPs encompassing the candidate genes (flanking the genes within 1 Mb)
were examined for consistency with an autosomal recessive mode of inheritance.

Whole exome sequencing
Whole exome sequencing (WES) data were generated for the dam, two affected
siblings, and an unaffected sibling. Genomic DNA (1 µg) from each sample was
mechanically sheared to fragments of approximately 180-250 bp (Covaris LE220,
Woburn, MA, USA). Fragment sizes were verified for quality control (Fragment
Analyzer, Advanced Analytical, Ankeny, IA, USA). The fragment library was hybridized
with 120-mer biotinylated RNA baits from the SureSelect XT Canine All Exon kit
(Agilent, Santa Clara, CA, USA), which was designed based on the UCSC CanFam2
Ensembl and Refseq tracks as well as human protein alignments. Magnetic streptavidin
beads were used for purification according to the manufacturer’s instructions. Library
DNA was amplified, sequencing barcodes and adapters were added (Illumina), and
equimolar amounts of each sample were pooled. The pool was sequenced on both lanes
of a Rapid Flowcell on a HiSeq2500 instrument (Illumina), generating paired-end 2x100
bp sequences, comprising on average 6 GB per sample. Sequencing data were
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demultiplexed (Illumina bcl2fastq 1.8.2), sequencing adapters were trimmed (skewer
0.1.116), and the resulting sequence mapped to the canine genome (CanFam3.1) using
the Burrows-Wheeler Aligner (bwa 0.7.2-r351). PCR duplicates and low-quality
alignments were removed (samtools 0.1.18 and internal software). Variant calling was
performed using a dual pipeline of bcftools (0.1.17) and varscan (2.3.5), and internal
software was used to combine these files into a single variant call file (VCF) per sample.
Reads were visualized using Integrated Genomics Viewer (IGV) [27]. Known
variants from Ensembl dbSNP (Can Fam3.1) and from private whole genome sequence
databases were excluded. NEB was manually screened for variants predicted to have an
effect on the protein.

Genotyping of g.52734272
Primers for PCR were designed to capture a 489 bp region encompassing
g.52734272 (Forward 5′-AAGTCCCAGCAGCAACATAA-3′, Reverse 5′GTCCAAAGTGGTCGGTCCT-3′). Products were amplified using ReddyMix master
mix (Thermo Scientific, Waltham, MA, USA) with 0.4 µM primers, 50 ng DNA, and
water for a total volume of 25 µL. Thermal cycling conditions were as follows: 95°C for
5 min; 5 touchdown cycles of 95°C for 30 s, 58°C for 30 s reducing 1°C per cycle, and
72°C for 1 min; 31 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 1 min; and a 10 min
final elongation at 72°C. Direct sequencing was carried out with BigDye Terminator
using an ABI 3730xl Genetic Analyzer to validate g.52734272.
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Using the same primers and thermal cycling conditions described above,
genotyping of g.52734272 in unrelated ABDs and other breeds was carried out through a
restriction enzyme digest with 5 µL PCR product and either BfaI CutSmart (New
England Biolabs, Ipswich, MA, USA) or FspBI FastDigest (Thermo Scientific) for total
reaction volumes of 25 µL and 15 µL, respectively. BfaI (FspBI) recognizes and cleaves
(^) the following sequence: 5′- C^TAG -3′. Digests were visualized on a 1.2% agarose
gel, where wild type alleles are uncut (489 bp) and mutant alleles are cut once (248 bp
and 241 bp).

Gel electrophoresis and western blotting
Frozen tissue samples were ground to a fine powder using a glass mortar and
pestle chilled in liquid nitrogen. After 20 min of priming at -20°C, tissue was
resuspended in a 1:1 mixture of an 8 M urea buffer (8 M urea, 2 M thiourea, 0.05 M TrisHCl, 0.075 M dithiothreitol, as well as 3% SDS and 0.03% bromophenol blue, pH 6.8)
and 50% glycerol with protease inhibitors (0.04 mM E-64, 0.16 mM leupeptin, and 0.2
mM PMSF). The solutions were mixed in a 60°C water bath for 4 min, followed by a 10
min incubation at the same temperature. Residual debris was removed via centrifugation
at 13000 rpm, and the supernatant was flash frozen for storage at -80°C. Initial protein
analysis was done via a 2-7% gradient acrylamide gel. Western blot was performed on
the samples using 0.8% agarose gels run at 15 mA per gel for 2 hours and 50 minutes.
Following this, they were transferred onto Immobilon-P PVDF membranes (Millipore,
Billerica, MA, USA) using a semi-dry transfer unit (Bio-Rad, Hercules, CA, USA) for

35

2.5 h at 164 mA. Membranes were briefly stained with Ponceau S to check for transferred
proteins. Following removal of the stain, membranes were incubated with primary
antibody at 4°C overnight. Nebulin N-terminal and C-terminal expression was quantified
using primary antibodies specific to those regions (Myomedix #6969 and #6964
respectively, http://www.myomedix.com). Expression was normalized to the integrated
optical density of myoglobin heavy chain (MHC) obtained from the Ponceau S staining.
The fluorescence of the western blots was analyzed using Odyssey Infrared Imaging
System. Ponceau S images were analyzed with One-D scan EX (Scanalytics Inc.,
Rockville, MD, USA).

Results
Affected dogs could independently ambulate, had generalized atrophy, and the
myopathy was relatively non-progressive (Supplemental video). Atrophy of the cervical
and dorsal thoracic limb muscles was noted with bilateral hypertrophy of the triceps
muscles. Serum creatine kinase (CK) activities were mildly elevated. Electromyography
(EMG) revealed spontaneous electrical activity, consisting mainly of fibrillation
potentials, within the proximal appendicular muscles of the thoracic limbs and the
cervical paraspinal musculature. Motor nerve conduction velocity (MNCV) testing
showed a mild decrease in the latency of the tibial and ulnar nerves. Respiratory
difficulties were not present.
A marked variability in myofiber size and generalized atrophy was present in
muscles from the affected ABDs (Fig. 1a) compared to control muscle (Fig. 1d). The
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predominant abnormality found in >50% of the muscle fibers from all affected muscles
examined was rod-like inclusion bodies highlighted with the modified Gomori trichrome
stain (Fig. 1b); these structures were not observed in control muscles (Fig. 1e) or with
H&E staining (Fig. 1a,d). Rod-like structures tended to be centralized or peripherally
distributed in the muscle fibers and were present in both slow twitch type 1 and fast
twitch type 2 muscle fibers. Atrophic fibers were also of both fiber types (Fig. 1c,f).
Numerous rods were apparent along the long axis parallel to that of the muscle filaments
(Fig. 1g). The rods were in structural continuity with Z disks (Fig. 1h), had the same
electron density as the Z lines of adjacent sarcomeres, and had a similar lattice pattern of
periodic cross-striations.

37

Figure 1. Histopathology establishes NM. Cryosections from the triceps muscle of an affected pup (a–
c) and archived control triceps muscle (d–f) were stained with H&E (a, d), modified Gomori trichrome
(b, e) and following incubation with monoclonal antibodies against type 1 and type 2 myosin heavy
chains (c, f). Excessive variability in myofiber size and atrophy were observed in the affected muscle
with the H&E stain (a) compared to control muscle (d). Numerous myofibers in the affected muscle
contained rod bodies (b, arrows) not evident in control muscle (e). Both type 1 and type 2 fibers were
atrophic (c) with fibers of both fiber types similar in size in control muscle (f). Bar 50 µm for
images a–f. By electron microscopy, numerous electron dense rods were apparent along the long axis
parallel to that of the muscle fiber (g). The rods were in structural continuity with Z disks (h), had the
same electron density as the Z lines of adjacent sarcomeres, and had a similar lattice pattern of periodic
cross striations. Bar 0.18 µm for images g and h

The absence of disease in the sire and dam indicates that transmission is likely
autosomal recessive. We hypothesized that the parents were heterozygous for a
deleterious allele inherited identical-by-descent through a common grandparent and that
their affected progeny were homozygous. Allelic inheritance was manually evaluated for
28 polymorphic SNPs within or flanking the 10 candidate genes; only markers
representing TNNT1 (CFA1) and NEB (CFA19) were consistent with a simple autosomal
recessive pattern (Table 1).
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Gene
(Chr)
TNNT1
(1)
ACTA1
(4)

TPM3
(7)

CFL2
(8)
TPM2
(11)
NEB
(19)
LMOD3
(20)
KLHL40
(23)
KBTBD13
(30)
KLHL41
(36)

SNP
position
105264488
105432142

AG
GG

AG
AG

GG
AG

GG
AG

AG
GG

105598975

GG

CG

CG

CG

GG

106497529
12713391
12875911
45997866
46022207*

AG
AG
AG
CC
AT

AG
AA
AA
AC
AA

AA
AG
AG
CC
AA

AA
AG
AG
CC
AT

AG
AA
AA
CC
AT

46034262*
46049585*
46303991
16507437
16587360
55241525*

AC
AG
CC
CC
GG
AC

AA
AG
AC
AC
AG
CC

AA
AA
CC
CC
GG
CC

AC
AG
CC
AC
AG
AC

AC
AG
CC
CC
GG
AC

55248320*
55761948*
55777049*

AA
GG
GG

AG
AG
AG

AA
GG
GG

AG
GG
GG

AA
GG
GG

55824838*
25536336
25605665

AG
AG
AA

AG
AA
GG

AA
AA
AG

AA
AA
AG

AG
AG
AG

25625642
14709678
14867876
32370798
32443189
32458624

AG
AC
AG
AG
AG
AC

AA
AA
GG
GG
GG
AA

AA
AC
AG
GG
GG
AA

AA
AC
AG
GG
GG
AA

AG
AC
AG
AG
AG
AC

17244342
17280474

AG
AG

AA
GG

AA
AG

AA
AG

AG
GG

Table 1. Genotypes for the nuclear family are reported for polymorphic SNPs (CanFam2)
representing each of the 10 candidate genes. When possible, SNPs lying within the gene are used
(asterisks); otherwise, the most proximal flanking SNPs are reported. When present, flanking SNPs
(within 1 Mb) for which the affected dogs are homozygous are also shown. SNPs fitting a recessive
pattern of inheritance are highlighted in bold
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We conducted WES of four family members because of the large size of NEB.
Across the samples, exome coverage, mappable reads, yields, and mean quality scores
averaged 30X, 59 million, 6 Mb, and 37.1, respectively. VCFs were used to filter variants
within the two candidate genes for those fitting recessive transmission (homozygous
alternate in both affected dogs, heterozygous in the dam, and heterozygous or
homozygous reference in the unaffected sibling). This step eliminated all 11 variants
identified within TNNT1 and 343 variants in NEB. Thirty-six remaining variants in NEB
were filtered to remove common polymorphisms, non-coding variants, and nondamaging variants (Fig. 2a). Only one overtly deleterious variant was identified in NEB, a
nonsense mutation g.52734272 C>A, corresponding to human exon 169 (S8042X;
NP_001258137.1). In addition, we confirmed that no variants in the other eight candidate
genes segregated with the phenotype. The NEB nonsense mutation was verified by
Sanger sequencing (Fig. 2b) and was absent in 100 unrelated ABDs and five dogs each
from 24 other breeds, determined by restriction digest genotyping.
Protein analysis of the triceps biopsies from the affected dogs suggested a loss of
NEB, which was then confirmed via western blotting (Fig. 3a,b). These values were
quantified, revealing NEB expression at 0.3% and 16.2% of their wild-type counterparts
for the N-terminus and C-terminus, respectively (Fig. 3c,d).
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Figure 2. Filtering of NEB variants reveals S8042X. (a) Filtering parameters are shown to the left
with the number of rejected variants to the right. Total variants prior to each filtering parameter are
shown above the arrows, beginning with the total number of variants. (b) Chromatograms from Sanger
sequencing show the wild-type and mutant alleles.

Figure 3. Nebulin is drastically reduced in skeletal muscles with S8042X. (a) Protein analysis on a
2-7% gradient acrylamide gel reveals a clear loss of nebulin in muscles from affected dogs compared to
healthy controls. (b) Western blots for the same samples using antibodies to nebulin’s N- and Cterminus. (c) and (d) Average quantification (CTRL 1 and CTRL 2; AFF 1 and AFF 2) of western blots,
indicating a severe loss of nebulin protein in affected dogs.
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Discussion
Histological and clinical findings from the affected ABDs are consistent with
primary NM. While the nemaline rod bodies are hallmarks of the disease, these
morphological features provide little indication of subtype or genetic etiology. The most
common of the six subtypes is typical congenital NM, which is most often attributed to
mutations in NEB [1,2]. The clinical presentation of independent ambulation and
relatively non-progressive muscle weakness at two months of age in the ABDs is
consistent with typical congenital NM [28].
We used a bipartite approach to uncover a nonsense mutation in NEB causing
ABD NM. To refine the list of 10 known candidate genes, we generated genome-wide
SNP profiles. Affected dogs inherited identical SNP haplotypes spanning TNNT1 and
NEB; therefore, these genes were prioritized for further study. Together, they comprise
nearly 200 exons, rendering Sanger sequencing impractical. Instead, we utilized WES, an
approach that provides high exon read coverage and the data to parse the rest of the
exome if no mutations are found in candidate genes.
NEB, or nebulin, is a giant protein (600-900 kDa) that stabilizes the actin thin
filament of skeletal muscle sarcomeres and is critical for proper thin filament formation
and muscle contraction [29]. NEB mutations account for up to 50% of molecularly
characterized NM cases [30]; most are truncating [31]. NEB has a multitude of isoforms
achieved primarily through alternative splicing of three sets of exons (63-66, 143-144,
and 167-177); truncating NEB mutations are frequently found in the latter set. In general,
homozygous truncating mutations may be less tolerated in ubiquitously expressed exons
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[31]. Consistent with these trends observed in human myopathies, S8042X lies in the
alternatively spliced exons 167-177.
We elected to investigate NEB protein levels, rather than transcript presence, in
cases and controls due to limited tissue quantities. Protein gels show little banding in the
NEB region, a finding consistent with the absence of protein detected with the Nterminus anti-nebulin antibody. The C-terminus antibody showed a low level of protein
(~16% of the levels in the control tissues) but with a mobility slightly larger than that of
NEB in the control samples. It is possible that this is a unique splice isoform of nebulin
that has low abundance and excludes the N-terminus. Alternatively, the C-terminus
antibody may be cross-reacting with another protein similar in size or a degradation
product of a larger protein. We consider the cross-reactivity hypothesis more likely
because we have detected titin degradation products of a size similar to NEB that crossreact with NEB C-terminus antibodies in previous work. Regardless, our data suggest that
S8042X results in very low levels of NEB, probably due to nonsense-mediated decay.
The inability to successfully express normal levels of full-length nebulin likely underlies
the pathology of the affected ABDs.
While we report the first mutation causing NM in dogs, this is not the first
pathogenic variant described in canine NEB. Ahram et al. [32] identified NEB missense
mutations associated with primary angle-closure glaucoma (PACG) in Basset hounds.
Interestingly, affected Basset hounds display no clinical signs of NM [32]. Ocular
abnormalities were not identified in either of the ABDs with NM, nor are they associated
with human NM attributed to NEB.
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The recent development of WES enrichment kits for canines [33,34] will facilitate
faster discovery of pathogenic variants, particularly when candidate genes are sizable or
numerous. Massive parallel sequencing of several exome libraries in a single hi-seq lane
is an economical approach for sequencing of multiple individuals, relative to whole
genome resequencing, and permits simultaneous identification and filtering of variants.
To date, this report is one of few to use WES in a nuclear family to identify a pathogenic
variant in dogs [32,35]. Rather than requiring the widespread distribution of the ABD
mutation throughout the population in order to gather sufficient cases for analysis with
traditional methods, WES allowed us to detect the mutation directly in the two probands.
Although no carriers were found in a survey of unrelated ABDs (extended family
members were unavailable for study), a genetic test now exists for S8042X should NM
arise again in the breed. The identification of carriers holds potential for the development
of a colony for testing of therapeutic approaches for humans.
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Abstract
Background
Limb-girdle muscular dystrophies (LGMDs) are a heterogeneous group of inherited
autosomal myopathies that preferentially affect voluntary muscles of the shoulders and
hips. LGMD has been clinically described in several breeds of dogs, but the responsible
mutation(s) are unknown. The clinical presentation in dogs is characterized by marked
muscle weakness and atrophy in the shoulder and hips during puppyhood.
Methods
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Following clinical evaluation, the identification of the dystrophic histological phenotype
on muscle histology, and demonstration of the absence of sarcoglycan-sarcospan
complex by immunostaining, whole exome sequencing was performed on five Boston
terriers: one affected dog and three family members, and one unrelated affected dog.
Results
Within sarcoglycan-δ (SGCD), a two base pair deletion segregating with LGMD in the
family was discovered, and a deletion encompassing exons 7 and 8 was found in the
unrelated dog. Both mutations are predicted to cause an absence of SGCD protein,
confirmed by immunohistochemistry. The mutations are private to each family.
Conclusions
Here we describe the first cases of canine LGMD characterized at the molecular level
with the classification of LGMD2F.
Keywords
muscle, myopathy, sarcoglycanopathy, dog, LGMD

Background
Limb-girdle muscular dystrophies (LGMDs) are a heterogeneous group of
Mendelian disorders affecting voluntary muscles of the shoulders and hips [1]. While
proximal limb muscles are primarily affected in LGMD, other muscles may degenerate as
well, such as the heart and respiratory muscles [1]. Sarcoglycanopathies are a subset of
severe, recessive LGMDs (LGMD2C-F) that present in early childhood [2]. There are six
known sarcoglycan genes (SGCA, SGCB, SGCD, SGCG, SGCE, and SGCZ); the first
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four encode single-pass transmembrane glycoproteins (α-, β-, δ-, γ-sarcoglycans) and,
along with sarcospan, make up the tetrameric sarcoglycan-sarcospan complex (SGC). As
part of the dystrophin-glycoprotein complex, the SGC is critical for maintaining
sarcolemmal stability [3]. Mutations in SGCA, SGCB, SGCD, or SGCG can result in nonassembly of the SGC and, therefore, the absence of all four sarcoglycans from muscle of
affected patients [3,4]. There are only a handful of low frequency founder alleles in
human populations responsible for sarcoglycanopathies [5]; thus they are most commonly
caused by mutations in compound heterozygosity [6].
In the domestic dog (Canis familiaris), selective breeding practices encourage
pairing of recessive alleles inherited identical by descent (IBD). Accordingly, dogs have
an abundance of recessive disorders [7], including muscular dystrophies [8,9]. Most
canine muscular dystrophies are associated with dystrophin deficiency, and founder
alleles have been identified in several breeds [10,11]. Recently, two independent
mutations causing dystrophinopathy were described in Cavalier King Charles spaniels
[12,13].
The first report of LGMD associated with sarcoglycan deficiency in dogs
involved three breeds: Chihuahua, Cocker spaniel, and a seven-month-old male Boston
terrier from Colorado (Case 1), but mutations were not identified [8]. Four years later,
sarcoglycanopathy was described again in an unrelated four-month-old male Boston
terrier from Iowa [14] (Case 2). All dogs affected with sarcoglycanopathy had a clinical
dystrophic phenotype including muscle wasting, gait abnormalities, enlarged tongue,
dysphagia, and extremely elevated serum creatine kinase (CK) activities [8,14].
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Pathologic features were consistent with dystrophy, having myofiber degeneration,
regeneration, and calcific deposits [8,14]. Affected dogs lacked muscle α-, β-, and γsarcoglycans, confirmed by both western blotting and immunohistochemistry [8,14]. At
the time of evaluation, an antibody reactive with canine δ-sarcoglycan was unavailable.
Here, we describe a sarcoglycanopathy in a third family of Boston terriers from
Arkansas in which two puppies (Cases 3 and 4) from the same kennel but different litters
displayed clinical signs of LGMD, pathological changes consistent with a dystrophic
phenotype and immunohistochemical confirmation of absent or decreased sarcoglycans.
To identify the genetic basis for LGMD in the Boston terrier breed, we performed whole
exome sequencing (WES) of Cases 1 and 3 and related dogs. Evaluation of the
sarcoglycan genes revealed, to our surprise, two private deletions in SGCD: a 2 bp
deletion in exon 6 and a 19.4 kb deletion encompassing exons 7 and 8. Both cause a lack
of SGCD, resulting in LGMD2F.

Materials and Methods
Animals
Clinical details of Case 1 were previously published [8]. Biological samples from
Case 2 were not available. Female Boston terriers, ages 12 months and 5 months, and
from the same breeder in Arkansas (Cases 3 and 4), were evaluated for a chronic history
of progressive dysphagia, lack of appetite, drooling, muscle wasting, and greatly enlarged
tongues. Both dogs were examined by the same veterinarian in a clinical setting.
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DNA was extracted from diagnostic muscle biopsies of Cases 1 and 3 and whole
blood of unaffected relatives of Cases 3 and 4 using the DNeasy extraction kit (Qiagen,
Hilden, Germany). Muscle for isolation of DNA was unavailable from Case 4. Whole
blood samples or buccal swabs from unrelated, healthy Boston terriers were recruited,
and DNA was isolated following the Gentra PureGene protocol (Qiagen, Hilden,
Germany) or the MagJet Genomic DNA purification kit (ThermoFisher Scientific,
Waltham, USA). Genomic DNAs from unaffected dogs from multiple breeds were
available from DNA archives at Clemson University and CAG GmbH.
The dogs in this study were examined and tissues collected in a clinical practice
setting with the written consent of their owners. Studies on tissue biopsies and blood
samples were approved by the Institutional Animal Care and Use Committees (IACUC)
of Clemson University, the University of California San Diego, the University of Iowa,
and the Animal Experiment Board in Finland (ESAVI/7482/04.10.07/2015), as well as
the Baden-Württemberg veterinary office at the Landratsamt Tübingen Abt. 32:
Veterinärwesen und Lebensmittelüberwachung, Tübingen, Germany (Registriernummer:
DE 08 416 1038 21).

Histology and Immunofluorescence
Muscle specimens from Case 1 were previously obtained as biopsies and archived
at -80ºC at the Comparative Neuromuscular Laboratory, University of California San
Diego (CNL). Specimens from limb muscles, heart, and tongue of Cases 3 and 4 were
collected by a veterinarian following humane euthanasia at 1 year of age. Muscles were
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either refrigerated or immersion fixed in buffered formalin and shipped to the CNL.
Cryosections from all muscle specimens were processed by a standard panel of
histochemical stains and reactions [15].
Antibodies used for immunofluorescence were rabbit antibodies R98 anti- αsarcoglycan [16], R214 anti- δ-sarcoglycan [17], IIH6 anti- α-dystroglycan [18], R256
anti-sarcospan [19]; mouse antibodies 5B1 anti- β-sarcoglycan [19], 21B5 anti- γsarcoglycan [19], AP83 anti- β-dystroglycan [18], anti-dystrophin (AbCam), anticollagenVI (Fitzgerald), and anti-caveolin 3 (BD Transduction Laboratories); rat antiperlecan (NeoMarkers).
For secondary immunofluorescence, tissues were blocked with 10% goat serum
in phosphate-buffered saline, incubated in primary antibody overnight, washed, incubated
in Alexa Fluor 488, 594, or 647-conjugated anti- rat, rabbit, or mouse antibodies (Life
Technologies), respectively, and mounted using ProLong Gold mounting media (Life
Technologies). For α-dystroglycan, sarcospan, δ-sarcoglycan, and γ-sarcoglycan staining,
tissues were fixed in 2% paraformaldehyde, followed by incubations in 100 mM glycine
and 0.05% SDS prior to processing as described above. Images were acquired using a
VS120-S5-FL slide scanner microscope (Olympus) with VS-ASW software.

Parentage Testing
The Canine Genotypes Panel 1.1 (ThermoFisher Scientific) was used to verify
parentage of the experimental dogs. Samples were amplified according to manufacturer’s
instructions and separated and detected on an ABI 3730XL (Applied Biosystems,
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ThermoFisher Scientific). GeneMarker (Softgenetics, State College, PA, USA) was used
to assign peaks and determine genotypes according to ISAG nomenclature.

Whole exome sequencing
DNA from five Boston terriers (Case 1, Case 3, and three unaffected relatives of
Cases 3 and 4) was used for WES performed at CeGaT GmbH (Tübingen, Germany).
Genomic DNA (1 µg) from each sample was mechanically sheared to approximately
180–250 bp fragments using a Covaris LE220 Ultrasonicator (Woburn, MA, USA).
Fragment sizes were assessed for quality control purposes (Fragment Analyzer,
Advanced Analytical Technologics Inc.), and the Agilent SureSelect XT Canine All Exon
kit (Santa Clara, CA, USA) supplied the 120-mer biotinylated RNA bases with which the
fragment library was hybridized. Magnetic streptavidin beads were used for purification
according to the manufacturer’s protocol (Agilent). After amplification of library DNA,
adaptors and barcodes for sequencing were added (Illumina), and equimolar amounts of
each sample were pooled. Both lanes of a Rapid Flowcell were used to sequence the pool
on an Illumina HiSeq2500, generating 2x100bp paired-end sequences, resulting in
approximately 6 GB per sample. Illumina bcl2fastq 1.8.2 was used to demultiplex
sequencing data, skewer 0.1.116 was used to trim sequencing adapters, and the BurrowsWheeler Aligner (bwa 0.7.2-r351) was used to map the sequences to the canine genome
(CanFam3.1). Samtools 0.1.18 and internal software were used to remove PCR duplicates
and low-quality alignments. bcftools (0.1.17) and varscan (2.3.5) and internal software
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were used to call variants, and a single Variant Call Format (VCF) file was generated for
each sample using internal software.
IGV [20] and Genome Browse (Golden Helix [21,22] Inc., USA) were used to
visualize data, and the Ensembl dbSNP (Can Fam3.1 version) and whole genome
sequences (Clemson) were used to exclude variants.

Variant characterization and genotyping
2 bp deletion
The 2 bp deletion identified in Case 3 was verified by Sanger sequencing, using
primers designed to amplify SGCD exon 6 (Additional File 1: Table S1). The deletion
disrupts a BcoD1 restriction enzyme site, yielding a 406 bp and a 347 bp product,
representing mutant and wild-type alleles respectively. Unrelated Boston terriers and
dogs from other breeds were genotyped using either restriction digest or Sanger
sequencing.
19.4 kb deletion
To define the break points of the micro-deletion encompassing SGCD exons 7 and
8 and the 3' intergenic sequence, primers were designed in flanking sequences
(Additional File 1: Table S1). For genotyping, primer pairs were designed within the
deletion to amplify only wild type alleles, as well as flanking the deletion for
amplification of the mutant allele. Primer pairs were multiplexed for amplification using
Phire Hot Start II DNA polymerase (ThermoFisher) and products were resolved by gel
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electrophoresis. Products were initially verified via Sanger sequencing. The multiplex
PCR was used to test unrelated Boston terriers and dogs of other breeds.

Results
Clinical findings
Muscle wasting, dysphagia, exercise intolerance, lethargy, and failure to thrive
were accompanied by progressive gait abnormalities including a short, stilted gait in
Cases 3 (Fig. 1a) and 4. While there was no clinical indication of cardiomyopathy,
specific evaluations for heart disease by a veterinary cardiologist were not performed.
Clinical chemistry included markedly elevated activities of serum alanine
aminotransferase (ALT, 900IU/L, reference range 10-110 IU/L), aspartate
aminotransferase (AST, 920 IU/L, reference range 16-50 IU/L), and creatine kinase (CK,
>10,000 IU/L, reference range 50-275 IU/L). Progression of clinical signs necessitated
euthanasia at approximately 1 year of age for Case 3 and 5 months of age for Case 4.

Histology and immunofluorescence
A dystrophic phenotype including degeneration, regeneration, and calcific
deposits was evident in the skeletal muscle (Figs. 1b) and tongue (Fig 1c and d). Heart
muscle was histologically normal (left ventricle, not shown) from Cases 3 and 4.
Immunofluorescence staining of muscle cryosections showed markedly reduced or absent
localization of α-, β-, γ-, and δ-sarcoglycans and sarcospan in Cases 3 and 4 (Fig. 2).
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Figure 1. Histopathology of muscle biopsies from a female Boston terrier affected with
sarcoglycanopathy (Case 3). A hunch back stance was evident in the dog (a). H&E stained
cryosections from a representative limb muscle (b) showed degenerative changes and calcific deposits
(black arrow). Similar degenerative changes and calcific deposits were observed in the tongue (c). The
calcific deposits in the tongue were highlighted bright orange using the alizarin stain for calcium (d).

In contrast, staining for localization of α- and β-dystroglycans, dystrophin, caveolin 3,
and perlecan was similar to control muscle (Fig. 3). Staining for collagen VI was
increased in the endomysium compared to the control tissue, consistent with endomysial
fibrosis. Results of histology, immunofluorescence staining, and western blotting of Case
1 were described previously [8]. Staining for localization of δ-sarcoglycan in Case 1 was
performed on archived muscle cryosections and was similarly absent (not shown).
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Figure 2. Loss of SGC staining in Cases 3 and 4. Representative H&E and immunofluorescence of
cryosections from muscle of Cases 3 and 4, as well as control dog muscle. In control muscle,
antibodies to the SGC (α-, β-, δ-, γ-sarcoglycans: αSG, βSG, δSG, γSG), as well as sarcospan
(SSPN), localize to the sarcolemma of the muscle fibers. Staining from each of these antibodies is
reduced in muscle from Cases 3 and 4.
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Figure 3. Representative immunofluorescence of cryosections from muscle of Cases 3 and 4, and
control dog muscle. Staining of α-dystroglycan (αDG), β-dystroglycan (βDG), dystrophin (DMD),
caveolin 3 (CAV3), collagen VI (COL6), and perlecan (PCAN) in Cases 3 and 4. Antibodies to α- and
β-dystroglycans, dystrophin, caveolin 3, and perlecan demonstrate sarcolemmal localization and
intensity that is comparable to control tissue. An antibody to collagen VI shows increased localization
to the endomysium compared to the control tissue, consistent with endomysial fibrosis.

Parentage testing
Parentage testing was performed to determine relationships between Case 3 and
three other dogs obtained from the same breeder. One relative was confirmed to be the
dam of Case 3 and is referred to hereafter as the obligate carrier. The test excluded the
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remaining two dogs from being full siblings of Case 3 or progeny of the obligate carrier.
Their relationship to the other dogs or to one another could not be determined.

Variant identification from WES
Disruption of any one of the sarcoglycans results in reduced immunostaining of
the entire SGC, both in LGMD patients and in animal models of sarcoglycanopathy
[23,24,25]. Therefore, genetic sequencing was necessary to identify the defective
sarcoglycan gene.
2 bp deletion
The candidate genes (SGCA, SGCB, SGCD, SGCG) were sequenced to an
approximate depth of 30X. For each gene, we manually screened the VCF file in IGV for
variants fitting a pattern of inheritance consistent with a rare recessive allele. We
expected both affected dogs to have inherited the causal mutation IBD from a common
ancestor; therefore, we searched for variants homozygous in Cases 1 and 3, heterozygous
in the obligate carrier, and heterozygous or homozygous wild-type in the two relatives.
No variants fit these criteria.
Because there was no known relationship between Cases 1 and 3, we considered
that they may have different genetic causes for LGMD. Thus, we excluded Case 1 and
searched again for the same pattern. Only one variant fit the pattern: a 2 bp deletion in
exon 6 of SGCD (Figure 4). We validated the deletion through Sanger sequencing and
determined that, in addition to the obligate carrier, one relative was heterozygous. The
deletion predicts the substitution of an aspartate for a glutamate (E178D) and creates a
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frameshift, leading to a premature stop codon two amino acids later (P180X) (Figure 4).
We genotyped 199 Boston terriers and 127 dogs from 33 other breeds; none possessed
the deletion.

Figure 4. Electropherogram showing the 2 bp SGCD deletion in Case 3. The top panel shows the
sequence from Case 3, while the lower panel shows the sequence from a healthy non-related Boston
terrier. The SGCD c.534_535delGA mutation leads to a frameshift and a premature stop codon two
amino acids later.

19.4 kb deletion
Using BAM files, we reexamined each candidate gene for variants homozygous in
Case 1 and absent from the other Boston terriers. This approach revealed a complete
absence of reads from the final two exons of SGCD (7 and 8) in Case 1, which was not
apparent from the VCF file. No other variants fit the pattern. We hypothesized that the
absence of reads represented a microdeletion and designed three primer pairs flanking
exons 6, 7, and 8. PCR amplification yielded a product for exon 6 but not exons 7 or 8 in
Case 1, providing further support for the presence of a deletion.
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It was not possible to characterize the deletion directly from WES because
intergenic and intronic sequences are minimized. Sequence coverage indicated that the
deletion was between SGCD exon 6 and TMD4. Furthermore, sporadic intronic and
intergenic fragments were present 5' of exon 7, beginning at chr4:53282570, and in the 3'
UTR, beginning at chr4:53261359, suggesting a maximum deletion size of 21,211 bp.
Primer pairs flanking this estimated deletion size yielded large products (~3-5 kb),
indicating a deletion approximately 2 kb smaller than suggested by WES. Sanger
sequencing of the breakpoint revealed a substitution (chr4:53262018-53262020,
ATG>CC), followed by 9 bp that were unchanged before a deletion of 19,403 bp
(chr4:53262030-53281432) (Figure 5). We genotyped 201 Boston terriers and 91 dogs of
19 other breeds and did not find any carriers.

Figure 5. Schematic and sequence showing the breakpoints of the 19,403 bp SGCD deletion in
Case 1. Note that SGCD is annotated on the minus strand. Whole exome sequence from a healthy dog
and Case 1 are aligned to the reference genome, visualized in Golden Helix GenomeBrowse [21,22].
Case 1 has no coverage of exons 7 and 8 and flanking regions. Sequence of the wild type and Case 1
alleles show the precise breakpoints. Nucleotides 5′ and 3′ of the breakpoint are in bold blue and orange
typeface, respectively. A substitution (chr4:53262020-53262018,CAT>GG) is found 9 bp downstream
of the microdeletion and is shown in bold red typeface
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Discussion
Sarcoglycanopathies in humans are rare genetic disorders, with an incidence of
one in every 178,000 human births [26]. To date, only small animal models are available
for study: gene targeted mouse models for α-, β-, δ-, and γ-sarcoglycanopathy [27] and a
spontaneous hamster model for δ-sarcoglycanopathy [28,29]. Here, we have
demonstrated that a naturally occurring muscular dystrophy in a Boston terrier family is a
sarcoglycanopathy, consistent with two previously published case reports in the breed.
Given that cases have been described in three Boston terrier families, we expected a
single recessive allele, present at a very low frequency within the breed, to underlie all
cases. Instead, we uncovered independent mutations in the two families studied herein.
Unfortunately DNA from Case 2 [14] was not available to determine whether this dog
shared one of the mutations described herein, a different mutation in SGCD, or a
pathogenic variant in another gene.
Both families possessed mutations in SGCD, which encodes δ-sarcoglycan.
Canine SGCD is located on CFA 4 and organized into eight exons that form a 1,297 bp
mRNA transcript [30]. Human (XP_016865213.1) and dog (XP_013968526.1) amino
acid sequences share 98% identity. Despite being the largest of the sarcoglycan genes,
SGCD least commonly causes sarcoglycanopathy, with the majority of human cases
attributed to changes in SGCA [31]. Thus, it is not only surprising that the Boston terriers
had independent mutations causing sarcoglycanopathy, but that both had pathogenic
alleles of SGCD. Curiously, the only other naturally occurring model of a
sarcoglycanopathy, the Syrian hamster, also harbors an SGCD deletion [29].
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Mutations of SGCD cause LGMD2F, and although clinical presentation is largely
similar among the four sarcoglycanopathies, this is the only subtype not consistently
characterized by concomitant cardiomyopathy [1]. The absence of heart involvement in
Boston terriers is consistent with this classification; however, because the affected dogs
were euthanized at an early age it is unknown if muscle degeneration would have
progressed to involve the heart.
Immunohistochemistry illustrated a lack of the SGC in both cases, but provides
no indication as to whether SGCD is abnormal or absent altogether. Due to limited
sample availability, collected tissues were prioritized for histopathological analysis and
genomic DNA sequencing. RNAs were thus unavailable to investigate the consequence
of the deletions on SGCD transcripts. The 2 bp pair deletion predicts a premature stop
codon in exon 6, possibly causing nonsense-mediated decay. The 19.4 kb micro-deletion
eliminates the last two exons of SGCD; the complete loss of an SGCD exon is rare [5]. It
is hypothesized that exon 6 would splice to one or more cryptic sites, triggering either
nonsense-mediated decay and/or the production of mutant protein. It is likely that mutant
SGCD would cause assembly of the SGC to fail, resulting in LGMD [3,32].
WES is a cost-effective method for the sequencing of multiple family members
and has been used successfully to identify LGMD mutations in humans [33]. It was an
advantageous choice over transcriptome sequencing in this study because SGCD
transcripts would have been absent in Case 3 and possibly Case 1 as well, necessitating
additional sequencing of SGCD to identify the causative mutations. In dogs, WES has led
to the identification of alleles underlying progressive retinal atrophy, primary angle
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closure glaucoma, and nemaline rod myopathy using small numbers of related cases
[34,35,36,37,38] but is not ideal for detecting intergenic deletions or genomic
rearrangements [39]. The development of improved WES enrichment kits for dogs
[39,40] will facilitate future detection of disease variants in canine models.

Conclusion
The identification of canine models of disease holds promise for new advances in
the understanding and treatment of analogous human diseases. For example, the wellcharacterized Golden retriever model of Duchenne muscular dystrophy (DMD) has
proven to be an invaluable resource for gene therapy and other trials [41,42]. Here we
have clinically and genetically characterized the first large animal model of
sarcoglycanopathy.
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Abstract
Juvenile dermatomyositis (JDM) is a chronic inflammatory myopathy and
vasculopathy driven by genetic and environmental influences. Here, we investigated the
genetic underpinnings of an analogous, spontaneous disease of dogs also termed
dermatomyositis (DMS). As in JDM, we observed a significant association with a
haplotype of the major histocompatibility complex (MHC) (DLA-DRB1*002:01/DQA1*009:01/-DQB1*001:01), particularly in homozygosity (P-val=0.0001). However,
the high incidence of the haplotype among healthy dogs indicated that additional genetic
risk factors are likely involved in disease progression. We conducted genome-wide
association studies in two modern breeds having common ancestry and detected strong
associations with novel loci on canine chromosomes 10 (P-val=2.3X10-12) and 31 (Pval=3.95X10-8). Through whole genome resequencing, we identified primary candidate
polymorphisms in conserved regions of PAN2 (encoding p.Arg492Cys) and MAP3K7CL
(c.383_392ACTCCACAAA>GACT) on chromosomes 10 and 31, respectively. Analyses
of these polymorphisms and the MHC haplotypes revealed that nine of 27 genotypic
combinations confer high or moderate probability of disease and explain 93% of cases
studied. The pattern of disease risk across PAN2 and MAP3K7CL genotypes provided
clear evidence for a significant epistatic foundation for this disease, a risk further
impacted by MHC haplotypes. We also observed a genotype-phenotype correlation
wherein an earlier age of onset is correlated with an increased number of risk alleles at
PAN2 and MAP3K7CL. High frequencies of multiple genetic risk factors are unique to
affected breeds and likely arose coincident with artificial selection for desirable
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phenotypes. Described herein is the first three-locus association with a complex canine
disease and two novel loci that provide targets for exploration in JDM and related
immunological dysfunction.

Author summary
Juvenile dermatomyositis (JDM) is an autoimmune disease of the skin and muscle
influenced by both genetic and environmental components. Although genes independent
of the MHC are thought to contribute to disease pathogenesis, their identification has
been complicated by a paucity of biological samples, disease heterogeneity, and
genetically diverse subjects. A naturally occurring inflammatory disease of domestic
dogs, also termed dermatomyositis (DMS), is analogous to JDM and is the only animal
model available for genetic study. We first determined that, as in JDM, a particular MHC
haplotype confers susceptibility to DMS. Capitalizing on the genetic isolation of dog
breeds and extremely low MHC diversity within affected breeds, we used multibreed
genome-wide association studies to identify two novel loci. Through genome
resequencing and additional genotyping, we uncovered highly associated polymorphisms
in conserved positions of PAN2 and MAP3K7CL. Analysis of three-locus genotypes
revealed uniquely high frequencies among affected breeds and nine allelic combinations
that confer moderate or high risk for DMS. The pattern of disease probability illustrates
the presence of gene-gene interaction, as well as an inverse correlation between age of
onset and number of risk alleles. This study highlights the utility of canine models for

80

mapping susceptibility loci in complex diseases and detecting patterns of genetic
interactions obscured in diverse human populations.

Introduction
Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy that causes a
characteristic skin rash (heliotrope rash across the eyelids and Gottron’s papules on the
bony prominences) and proximal muscle weakness [1]. It is the most frequently
diagnosed childhood inflammatory myopathy, comprising 80% of all cases [1] and
affecting 3.2 in every million children between the ages of 2 and 17 within the USA [2].
Prognosis is positively correlated with early diagnosis and swift treatment with
corticosteroids and/or immunosuppressants [1,3]. While treatment of JDM is much
improved overall, many children still suffer from chronic flare-ups [1].
Though the etiology is unknown, JDM is thought to be triggered by exposure to a
virus or other environmental agent. Manlhiot et al. [4] reported that 71% of JDM patients
had a clinical history consistent with infection prior to symptoms. Investigations into the
class II major histocompatibility loci (MHC), TNF, and IL1 identified several
susceptibility and protective alleles, but their collective contribution to pathogenesis is
poorly understood [5-8]. Recent genome-wide association studies (GWASs) to identify
additional susceptibility loci in JDM confirmed a strong association with the MHC but
failed to detect novel major risk factors, likely because of a paucity of biological samples
and genetically heterogeneous populations [9,10].
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In domestic dogs, an inflammatory vasculopathy of the skin and muscle, also
termed dermatomyositis (DMS), is clinically, histologically, and immunologically similar
to JDM and provides the only animal model available to study genetic risk factors [1116]. The earliest clinical signs of DMS are crusting and scaling on the face, ears, tail tip,
and/or across the bony prominences of the limbs and feet [17-19] (S1 Fig). Alopecia and
more extensive skin lesions may develop over time, resulting in dermal scarring
associated with erythema and mottled pigmentation [17,19]. Lesions persist for weeks to
months, and may or may not chronically recur [17]. Muscle wasting manifests as atrophy
of the head musculature; difficulty eating, drinking, and swallowing; and an atypical,
high-stepping gait [17,19].
Similar to JDM, DMS is an immune-mediated disease [13,18,20] that typically
develops following an environmental trigger, such as vaccination or viral infection, and is
exacerbated by subsequent stressors like exposure to UV light [13,17,21,22]. Anecdotal
reports indicate that rabies vaccination, parvovirus infection, owner surrender, or
mistreatment commonly precede disease onset. Consistent with an environmental trigger,
age at onset is variable with many cases occurring between seven weeks and six months
of age, but others not developing until well into adulthood [17-19,23].
DMS is diagnosed almost exclusively in the genetically [24] and phenotypically
similar collie and Shetland sheepdog breeds, suggesting the presence of a strong heritable
component(s) arising from ancestors common to both breeds. A 1980s study of disease
transmission in the collie eliminated simple Mendelian modes of inheritance [14]. In two
test matings, an affected male collie sired litters from an affected collie and a healthy
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Labrador retriever. All six collie puppies were affected with variable degrees of severity,
while three of the four mixed breed puppies developed milder forms of DMS.
Retrospective pedigree analyses of the collie sire and dam showed a complete absence of
affected ancestors [14].
The availability of a naturally-occurring canine model provides a new opportunity
for the identification of genetic risk factors of JDM. The conserved genomic backgrounds
of genetically isolated dog breeds have enabled detection of risk loci in complex diseases
that are often obscured by heterogeneity within human cohorts [25-30]. Here, we
evaluated class II MHC haplotypes, performed multibreed GWASs, and generated whole
genome and transcriptome sequencing data to dissect the genetic basis of DMS. We
uncovered common polymorphisms of the MHC and two novel loci that are strongly
associated with DMS, as well as patterns of allelic inheritance that explain 93% of cases
studied. A genetic test is now available to determine the likelihood of a dog developing
DMS and to facilitate breeding decisions that avoid progeny having high-risk genotypes.

Results and Discussion
Association of a major histocompatibility complex haplotype
Given the involvement of MHC genes in JDM, we first determined alleles of the
highly polymorphic canine MHC class II dog leukocyte antigen (DLA) genes: DLADRB1, -DQA1, and -DQB1. Two locus (DLA-DRB1 and -DQB1) and three locus (DLADRB1, -DQA1, and -DQB1) haplotypes were first generated for 50 collies and 117
Shetland sheepdogs, respectively. Because all observed haplotypes contained a unique

83

DLA-DRB1 allele, the 355 remaining dogs were genotyped for this locus only and the
haplotype was inferred (Table 1).

DLA-DRB1*/-DQA1*/-DQB1*
002:01/009:01/001:01
006:01/050:11/007:01
015:01/009:01/001:01
DLA-DRB1*/-DQA1*/-DQB1*
†

002:01/009:01/001:01
015:01/009:01/001:01
023:01/003:01/005:01
Other haplotypes

COLLIE
Cases
Controls
OR
(2n=80)
(2n=370)
74
353
0.59
0
3
6
14
2.06
SHETLAND SHEEPDOG
Cases
Controls
OR
(2n=184) (2n=410)
158
301
2.20
1
6
0.37
24
102
0.45
1
1
-

95% CI

P-value

0.23-1.56
0.77-5.54

0.40
0.23

95% CI

P-value

1.38-3.52
0.04-3.08
0.28-0.73
-

0.0010
0.4454
0.0011
-

Table 1. Frequency of DLA-DRB1/-DQA1/-DQB1 haplotypes in collies and Shetland sheepdogs.
The number of times each haplotype was observed is reported for cases and controls with odds ratios
(OR), 95% confidence intervals, and Fisher’s exact two-tailed P-values. Significant statistics are
bolded.
†
71 out of 92 cases and 109 out of 205 controls were homozygous for the 002:01/009:01/001:01
haplotype (OR=2.98, 95% CI=1.70-5.21, P-val=0.0001).

We observed remarkably low DLA diversity among collies, with only three
haplotypes present in 225 collies worldwide. This lack of heterogeneity precluded
detection of associations with DMS, as 91% of collies were homozygous for the
haplotype DLA-DRB1*002:01/-DQA1*009:01/-DQB*001:01. In 297 Shetland
sheepdogs, we identified two predominant haplotypes, 002:01/009:01/001:01 and
023:01/003:01/005:01. The former was over-represented among cases (P-val=0.0010,
OR=2.20), primarily because of increased homozygosity (P-val=0.0001, OR=2.98). We
therefore conclude that 002:01/009:01/001:01 is a risk factor for DMS and that
homozygosity confers increased susceptibility. Under the assumption that the causal
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alleles derive from an ancestor common to both breeds, we extrapolate the observed DLA
risk to collies. The high frequency of the DLA risk haplotype in both populations
indicates that additional loci must influence disease progression.

Genome-wide association studies reveal signals on chromosomes 10 & 31
We conducted an independent GWAS for each breed, using a total of 97 cases (31
collies, 66 Shetland sheepdogs), 68 controls (23 collies, 45 Shetland sheepdogs), and
98,520 SNPs after filtering. In collies, a single signal (P-val=1.47X10-8) composed of 17
SNPs at the centromeric end of chromosome 10 exceeded Bonferroni significance (Fig
1A). In Shetland sheepdogs, this association was replicated (P-val=2.56X10-7), and a
second signal (P-val=1.83X10-9) composed of 11 SNPs surpassing Bonferroni
significance was detected on chromosome 31 (Fig 1B). Both associations persisted in a
combined breed analysis (chr10: P-val=2.3X10-12, chr31: P-val=3.95X10-8) (S1 Table, S2
Fig); although the breeds possessed a common haplotype on chromosome 31, the
Shetland sheepdogs appeared to drive this association. No associated SNPs were detected
near the MHC loci on chromosome 12, likely a result of high homogeneity in our cohort
and poor SNP coverage on the array [25].
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Figure 1. Manhattan plots of DMS GWASs in two breeds. (a) Collies: 31 cases and 23 controls.
(b) Shetland sheepdogs: 66 cases and 45 controls. The –log10P-values (y-axis) for 98,520 Illumina
SNPs are plotted against chromosome position (x-axis). The threshold for Bonferroni significance
is shown as a black horizontal line. The P-value and position (canFam3) of the lead SNPs are
reported.

On chromosome 10, 97% of all affected dogs were homozygous or heterozygous
for the risk alleles of the lead SNPs. On chromosome 31, 88% of affected Shetland
sheepdogs, but only 39% of affected collies, shared the risk alleles of the lead SNPs. As
neither locus appeared to be independently necessary for disease development, we
surveyed the extent of regional linkage disequilibrium (LD) to demarcate candidate
intervals of ~1.33 Mb on chromosome 10 (Fig 2A) and ~696 kb on chromosome 31 (Fig
2B), harboring ~65 and 6 genes, respectively. The large size of the chromosome 10
region is attributed to lower recombination rates near the centromere and a dearth of
informative SNPs.
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Figure 2. Regional plots depicting LD at two associated loci. Association results (-log10P) for (a)
combined breed GWAS on chromosome 10 and (b) Shetland sheepdog GWAS on chromosome 31 are
color-coded based on pairwise LD (r2) with the lead SNPs (purple diamond). Dotted lines demarcate the
candidate interval. Genes within the region (based on hg18) are shown below the plot with chromosome
positions reported in canFam3. On chromosome 10, the gene track is zoomed in to represent the
candidate interval only; 4 genes were omitted from the figure (DNAJC14, LOC440104, MMP19, and
SLC39A5).
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Identification of candidate variants in PAN2 and MAP3K7CL
Whole genome resequencing was performed for four affected dogs (three collies
and one Shetland sheepdog) and two unaffected collies, resulting in 17X to 41X
coverage. Variants were filtered for those lying within our delineated intervals (chr10:11,333,693; chr31:24,026,411-24,722,836) and following the inheritance pattern of the
most significantly associated SNPs in the affected dogs (S2 and S3 Tables). Five
intergenic and two intronic variants were unique to these breeds (i.e., not present in the
Boxer reference genome, dbSNP, or 27 whole genome sequences from 16 other breeds);
however, most were in repetitive regions and none were in conserved positions. Thus, the
pathogenic variants were likely to be common polymorphisms, so we next prioritized
variants within predicted exons and splice sites of genes expressed in skin for further
study.
To confirm exon/intron boundaries predicted by Ensembl 79 and establish
expression of variants in affected tissue, we generated RNAseq data. We obtained a
minimum of 89 million reads per tissue from active skin lesions of two affected dogs
(one collie and one Shetland sheepdog) and skin from one unaffected Australian shepherd
dog. All genes expressed in skin within the candidate regions were also expressed in
affected tissues. Seventeen exonic variants were expressed; seven of these were
nonsynonymous and evaluated using in silico programs [31-33] (Table 2).
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Position

Gene

A1/A2

AA
change

PolyPhen2

PANTHER

SIFT

CHROMOSOME 10
95042
121835
222809
331135
565958
627760
1127082
1228277
1239562
1286150
1333693

ITGA7
RDH5
MMP19
SUOX
ANKRD52
PAN2
RDH16
NAB2
STAT6
LRP1
LRP1

T/C
G/A
T/G
A/G
G/C
G/A
C/T
G/C
G/A
C/T
G/A

Val/Val
Ala/Ala
Gln/Pro
His/Arg
Ser/Cys
Arg/Cys
Ala/Ala
Gly/Arg
Thr/Met
Asn/Asn
Gln/Gln

0
0
0.92
1
0
0.98
-

91
85
361
1628
85
361
-

0.43
N/A
0.02
0
N/A
0.05
-

T/C
Indel/A/C
A/G
A/G
A/G

Ala/Ala
5′ UTR
5′ UTR
Asn/Asp
Glu/Glu
Pro/Pro

N/A
N/A
0.007
-

N/A
N/A
324
-

N/A
N/A
0.21
-

CHROMOSOME 31
24068039
24132273
24132343
24292521
24294659
24295208

CCT8
MAP3K7CL
MAP3K7CL
BACH1
BACH1
BACH1

P-value
Cases n=93
Controls n=63
1.93X10-17
1.93X10-17
1.52X10-4
Cases n=63
Controls n=45
2.09X10-11
1
-

Table 2. Expressed exonic changes on chromosomes 10 and 31. Alleles 1 (A1=minor allele) and 2
(A2=reference allele) are reported. Amino acid changes are based on the dog reference genome. Pvalues are reported for matched populations. Variants with PolyPhen2 scores ranging from 0.85-1,
PANTHER preservation time (in millions of years) >450my, and SIFT scores ranging from 0-0.05 are
considered deleterious/probably damaging. Variants more strongly associated with DMS than the most
associated SNPs from the array are bolded.

We genotyped a subset of our mapping population for three nonsynonymous
SNPs on chromosome 10 (ANKRD52 g.565958G>C, PAN2 g.627760G>A, and STAT6
g.1239562G>A) that were predicted to be deleterious or probably damaging by more than
one in silico program. The ANKRD52 and PAN2 variants were more strongly associated
with DMS than the lead SNP. These variants were in perfect linkage disequilibrium with
each other; however, PAN2 g.627760G>A was assigned damaging scores with higher
confidence by in silico programs (Table 2). We therefore focused further studies on
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PAN2 g.627760G>A, encoding p.Arg492Cys (XP_531635.3), although ANKRD52
cannot be excluded. On chromosome 31, we genotyped Shetland sheepdogs for a SNP
(g.24132343A>C) and an indel (c.383_392ACTCCACAAA>GACT, XM_846337.4),
both located in a 5′ non-coding exon of MAP3K7CL. Only the indel was associated with
DMS (Table 2, S3 Fig). In an expanded, combined population (132 affected and 390
unaffected collies and Shetland sheepdogs), both the PAN2 (P-val=2.08X10-35) and
MAP3K7CL (P-val=1.45X10-33) variants were highly associated with DMS (S4 Table).
PAN2 (or USP52) encodes the catalytic subunit of the poly(A) nuclease
deadenylation complex (PAN2-PAN3) and is one of two exonucleases involved in
mRNA degradation in eukaryotes [34,35]. Deadenylation plays a role in translational
regulation of inflammatory response [36]. Independent of this function, PAN2 also
stabilizes HIF1A transcripts via their 3′-UTR, which contain AU-rich elements (AREs),
and may be involved in regulating other transcripts having AREs [37]. HIF1A, a key
regulator of inflammation [38], and other ARE-containing transcripts, such as IL-6 [39],
are upregulated in JDM [40, 41]. PAN2 is widely expressed and highly evolutionarily
conserved [35]; human (NP_001120932.1) and dog (XP_013972628.1) amino acid
sequences share 98% identity.
MAP3K7CL (also known as TAK1L or C21orf7) is a poorly studied kinase gene
that is transcriptionally active in immunological tissues and expressed primarily in
peripheral blood leukocytes [42,43]. Human (NP_001273546.1) and dog
(XP_013965340.1) MAP3K7CL protein sequences share >90% identity. The
transcription factors RUNX3 and EP300 bind the 5′ non-coding exon of human
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MAP3K7CL (UCSC Genome Browser ENCODE Transcription Factor ChIP-seq track).
In this exon, the c.383_392ACTCCACAAA>GACT indel causes the loss of six
conserved base pairs, omitting a RUNX3 binding motif (P-val=2.07X10-3 from
TOMTOM [44]) (S3 Fig). RUNX3 has known roles in inflammatory response (e.g.,
thymopoiesis [45,46] and the TGF-β signaling cascade [47]), and it has been directly
implicated in a number of immune-related diseases [48-50]. Furthermore, SNPs
disrupting RUNX binding motifs in target genes confer susceptibility to autoimmune
rheumatic diseases, including psoriasis [51] and systemic lupus erythematosus [52].

Analysis of three-locus genotypes reveal gene-gene interactions
We next considered three-locus genotypes in our expanded, combined population
(132 affected and 390 unaffected dogs) where A=the PAN2 variant encoding
p.Arg492Cys, B=MAP3K7CL c.383_392ACTCCACAAA>GACT, and C=DLADRB1*002:01, lower-case letters denote wild type alleles (c represents any alternate
allele of DLA-DRB1). Only 4% of dogs possessed a three-locus genotype with cc, barring
further analysis of those nine genotypes. We considered nine of the remaining genotypes
to be low-risk, as less than 6% of dogs with these allelic combinations had DMS (Table
3). Among healthy dogs (Fig 3A), the most frequently observed genotypes were AabbCC
(24%) and aabbCC (15%). Based on penetrance, we classified five genotypes as
conferring moderate risk (33-50%) and four as high risk (90-100%) for DMS. All cases
possessed at least two risk alleles and all but one were homozygous for at least one risk
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allele. The most common genotypes of affected dogs (Fig 3B) were AaBBCC (20% of
cases), followed by AAbbCC, AABbCC, and AABBCC (17% of cases each).
Interestingly, only affected dogs possessed AABBCc or AABBCC (n=29),
indicating that DMS is fully penetrant in dogs having these combinations. Epistasis plots
illustrated that genotypes with at least one a or b allele confer a lower probability of
disease when a c allele is present, compared to their CC counterparts (Fig 3, compare C
and D). The plots also depicted a greater probability of disease than expected under a
strictly additive model, providing evidence for additive-by-additive epistasis between the
chromosome 10 and 31 loci [53,54]. We noted at least one ARE in MAP3K7CL,
presenting a mechanism for interaction with PAN2. No difference in gene interactions
was observed between the sexes (S4 Fig).
Information regarding age at onset or diagnosis was available for 91 dogs. We
compared dogs having two, three, or four risk alleles across PAN2 and MAP3K7CL and
observed an inverse correlation between age of onset and number of risk alleles (S5 Fig).
Dogs having four risk alleles developed DMS at a significantly younger median age (5
months) than did dogs with only two risk alleles (18.5 months). The complete penetrance
of AABB genotypes, combined with an early age of onset, suggest that these dogs may be
hypersensitive to commonplace environmental stimuli (e.g., routine puppy vaccinations).
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Figure 3. Three-locus genotype disease probabilities and frequencies (132 cases, 390 controls).
Word clouds of three-locus genotypes illustrate frequency differences between (A) controls and (B)
cases with high-risk genotypes in red, moderate-risk in yellow, and low-risk in blue. Probability of
disease (y-axis) for all combinations of PAN2 (x-axis) and MAP3K7CL genotypes are plotted in dogs
(C) homozygous and (D) heterozygous for DLA-DRB1*002:01.
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Shetland
sheepdogs

Collies
Genotype

aabbcc
aabbCc
aabbCC
Aabbcc
AabbCc
AabbCC
aaBbcc
aaBbCc
aaBbCC
AaBbcc
AaBbCc
AaBbCC
AAbbcc
AAbbCc
AAbbCC
aaBBcc
aaBBCc
aaBBCC
AaBBcc
AaBBCc
AaBBCC
AABbcc
AABbCc
AABbCC
AABBcc
AABBCc
AABBCC

Cases
(n=40)

Controls
(n=185)

Cases
(n=92)

Controls
(n=205)

0
0
1
0
0
2
0
0
0
0
0
0
1
4
15
0
0
0
0
0
3
0
0
11
0
0
3

1
5
43
0
3
71
0
1
10
0
0
13
0
6
31
0
0
0
0
0
0
0
0
1
0
0
0

0
0
1
0
1
2
0
0
0
0
0
2
0
1
7
0
0
6
2
5
23
3
2
11
0
7
19

1
18
17
3
15
23
5
21
32
1
14
23
0
1
3
1
6
7
1
5
3
0
4
1
0
0
0

Combined
Penetrance
(%)
42
39
46
50
90
33
92
100
100

Risk*
low
low
low
low
low
low
low
low
low
moderate
moderate
low
moderate
moderate
high
moderate
high
high
high

95%
Confidence
Interval
0-0.842
0-0.148
0.004-0.112
0-0.708
0.001-0.260
0.011-0.101
0-0.522
0-0.154
0.084
0-0.975
0-0.232
0.006-0.177
0.025-1
0.152-0.723
0.265-0.532
0-0.975
0.0459
0.192-0.749
0.094-0.992
0.187-0.813
0.762-0.978
0.292-1
0.043-0.777
0.730-0.990
0.590-1
0.846-1

Pvalue
**
1
0.0023
0
0.577
0.060
0
0.399
0.002
0
1
0.028
0.002
0.253
0.194
0.021
1
0.348
0.107
0.160
0.136
0
0.016
0.647
0
0.0001
0

Table 3. Distribution of three-locus genotypes in 132 cases and 390 controls with penetrance,
95% confidence intervals, and P-values. Significant values in bold.
*Risk interpretations were only made for three-locus genotypes observed at least five times.
**P-values are calculated for each genotype compared to the population as a whole (0.253, 132 affected
dogs out of 522 total dogs).
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Collies and Shetland sheepdogs have uniquely high frequencies of associated alleles
All three identified variants associated with DMS are polymorphisms present in
several breeds, raising the question: why are other breeds rarely, if ever, affected by
DMS? We genotyped five or more unrelated individuals from each of 30 diverse breeds
for all three loci (Fig 4). The only other breeds to possess all three risk alleles were
Cardigan Welsh corgis and Cairn terriers. Three Jack Russell terriers had moderate-risk
genotypes (AAbbCc), as did one Cardigan Welsh corgi (AABbCc); both breeds are
occasionally diagnosed with dermatomyositis-like disease [56,57]. None of the 229
individuals possessed a high-risk genotype (S5 Table). Interestingly, Labrador retrievers
had both B and C, which could have enabled moderate or high risk genotypes (AaBBCc
or AaBBCC) in puppies from the outcross mating described by Haupt et al. [14].
Combined frequencies of risk alleles in other breeds were dramatically lower than
those observed among collie and Shetland sheepdog populations, and homozygosity for a
risk allele (a characteristic of all moderate- to high-risk genotypes) was rare.
Additionally, breeds having a high frequency of one risk allele had few or no risk alleles
at the other loci. For example, Cairn terriers had a high frequency of A (75%) but low
frequencies of B (19%) and C (3%), and no high- or moderate-risk genotypes were
observed among 18 individuals. These findings suggest that independently the
polymorphisms are neither deleterious nor selected against.
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Figure 4. Frequencies of DMS-associated polymorphisms across breeds. The number of alleles used
to calculate the frequencies is shown to the left of the breed name, if > 10. Risk allele frequencies (xaxis) for each gene are represented by a single, segmented colored bar: the PAN2 variant encoding
p.Arg492Cys is represented in purple, MAP3K7CL c.383_392ACTCCACAAA>GACT in gray,
and DLA-DRB1*002:01 in orange. The number of homozygous dogs observed is reported on the
corresponding color bar. Asterisks denote breeds lacking DLA-DRB1*002:01 in this study, but which
were previously reported to possess the allele [55].
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It is likely that recent artificial selection for phenotypes shared by collies and
Shetland sheepdogs led to increased frequencies of A. We propose that persistence of A in
these two breeds is attributed to linkage disequilibrium (D′=0.998) between wildtype
PAN2 (a) and another chromosome 10 allele, Merle of PMEL. In heterozygosity, Merle
causes a popular pigmentation pattern (see collie in Fig 1A), but homozygosity for the
allele results in severe hypopigmentation often with auditory and ocular defects [58].
Wildtype PMEL occurred on chromosomes with either A or a, whereas Merle was only
found in conjunction with a. Accordingly, the Merle phenotype was underrepresented in
affected dogs (P-value=0.0018), 64% of which were homozygous for A. Consistent
selection for heterozygosity (but not homozygosity) for Merle would simultaneously
encourage maintenance of both PAN2 alleles. To our knowledge, there are no loci on
chromosome 31 under positive selection for maintenance of a characteristic phenotype of
collies and/or Shetland sheepdogs.
Across five collie genomes, we observed a 1.2 Mb selective sweep on
chromosome 12 (S6 Fig) encompassing the MHC class II loci and leading to near fixation
of the 002:01/009:01/001:01 haplotype. We suggest that essentially all purebred collies
have increased susceptibility for DMS, conferred by homozygosity for allele C. The
Shetland sheepdog population has retained a less common second haplotype that permits
heterozygosity at the DLA loci, associated with a lower risk for developing DMS.
Ironically, this reduced risk may have masked the presence of otherwise high-risk
genotypes (i.e., AABb and AaBB) and hindered selection against A and B alleles.
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We observed striking allele frequency differences between the two affected
breeds at PAN2 and MAP3K7CL: collies had a higher frequency of A, 42% (25% in
Shetland sheepdogs), whereas Shetland sheepdogs had a higher frequency of B, 38% (5%
in collies) (Fig 4). Consequently, the frequency of observed allelic combinations varied
between the breeds. The most common genotypes in healthy dogs were aaBbCC in
Shetland sheepdogs, 16% (5% in collies), and AabbCC in collies, 38% (11% in Shetland
sheepdogs). Among affected dogs, AaBBCC predominated in Shetland sheepdogs, 25%
(8% in collies), whereas AAbbCC was the most frequent genotype in diseased collies,
38% (8% in Shetland sheepdogs). The latter finding is interesting given that AAbbCC is
only a moderate-risk genotype. Among collies having this genotype, 67% were
unaffected by age 8, whereas only 30% of Shetland sheepdogs with this genotype were
disease-free. This discrepancy in disease probabilities between breeds was unique to this
genotype. Further studies will be necessary to determine if other loci confer additional
risk for or protection from DMS.
The contribution of alleles from multiple loci explains the spontaneous
appearance of the disease in lines with no prior history [14] and has hindered elimination
of DMS in the absence of a genetic test. For example, a mating between two healthy dogs
having low risk genotypes (e.g., AaBbCC x AaBbCC) can produce puppies with low,
moderate, or high risk for DMS. This study has led to the first three-locus genetic test for
a complex disease of dogs, which will allow breeders to carefully reduce the frequency of
A and B among collie and Shetland sheepdog populations while preserving genetic
diversity and desirable breed characteristics.
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In a canine model of JDM, we have identified a complex pattern of causation
involving three independent loci, two of which offer new targets for exploration in JDM.
Furthermore, these data provide support for the involvement of genetic risk factors
independent of the MHC in human inflammatory myopathies. While further experiments
are necessary to determine the exact contribution of the chromosome 10 and 31 loci, our
findings suggest that DMS may result from an inability to properly regulate inflammatory
response. This work highlights the utility of the canine model for unraveling genetic
susceptibility conferred by common polymorphisms and/or gene-gene interactions in
complex diseases.

Methods
Ethics statement
All samples were obtained with informed consent according to protocols
approved by the Clemson University Institutional Review Board (IBC2008-17) and
IACUC (2012-039).

Study population.
Three populations were assembled: DMS-affected dogs (92 Shetland sheepdogs,
40 collies), control dogs for GWAS (45 Shetland sheepdogs, 23 collies), and unaffected
dogs (160 Shetland sheepdogs, 162 collies). Affected dogs were diagnosed either through
histopathology (75 Shetland sheepdogs, 30 collies) or by a veterinarian based on clinical
signs and elimination of demodectic mange, a differential diagnosis. Pedigrees were
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collected when available; some samples were obtained from affected dogs surrendered to
rescue organizations without paperwork. Twenty percent of affected dogs were collected
internationally, and in each case a regionally-matched control sample was obtained.
Control dogs for GWAS were eight years of age or older at time of collection, had no
known family history of DMS, had no personal history of skin disease, and were
unrelated to other study participants within two (most often three) generations. Pedigrees
were obtained from all control dogs. The population of unaffected dogs had no clinical
signs of DMS and were eight years of age or older at time of collection. This subset was
collected without regard to family history of DMS, presence of other skin disorders, or
relationship to other study participants. Archival samples from 229 dogs of 30 other
breeds were not closely related to each other to our knowledge.
Whole blood or buccal cells were obtained from each dog, and genomic DNA was
isolated according to the Puregene DNA Isolation protocol (Gentra). Skin punch biopsies
from active lesions or healthy tissue were also obtained from one Shetland sheepdog, one
collie, and one Australian shepherd dog and preserved in RNAlater (Ambion).

DLA class II genotyping.
The hypervariable regions of DLA-DRB1, -DQA1 and -DQB1 were sequenced
and genotyped according to protocols previously described [59-61]. DLA-DQA1 was
largely uninformative in collies and was inferred. Association of a haplotype or allele
state with DMS was assessed through Fisher’s exact tests, using VassarStats (Web Site
for Statistical Computation, Vassar College, Poughkeepsie, NY).
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Genome-wide association and LD analyses.
Genotyping was performed for 166 dogs (85 males and 81 females) using the
Illumina CanineHD BeadChip, containing 173,662 SNPs. One sample having call rates
<95% was excluded. SNPs having call rates <95%, minor allele frequencies <5%, and/or
significant deviation from Hardy-Weinberg equilibrium (P-value <0.0001) in the control
dogs were excluded. No evidence of genomic inflation was observed in the combined
Shetland sheepdog and collie analysis (λ=1.04). Fisher’s exact P-values were calculated
under a dominant model.
LD pairwise analysis was performed to calculate r2 values, which were plotted
using LocusZoom [62]. We calculated r2 values between SNPs on chromosome 10 using
all controls. For chromosome 31, r2 values were calculated using only control Shetland
sheepdogs because no association was detected in collies alone. Assuming that the
pathogenic variant would be in high LD with the lead SNP, candidate regions were
characterized by SNPs with pairwise r2 ≥ 0.6 and defined by the first flanking associated
SNPs in lower LD. Filtering and statistical analyses were conducted with SNP &
Variation Suite v8 (SVS, Golden Helix). All chromosome positions throughout the text
are reported in CanFam3.1.

Whole genome resequencing.
Three affected and two control collies were selected for whole genome
resequencing along with one affected Shetland sheepdog. Genomic DNA fragments of
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approximately 500bp were gel size selected for each sample and sequenced on two lanes
of an Illumina HiSeq 2000, generating 2x100 (collies) and 2x125 bp (Shetland sheepdog)
paired-end reads. 531 to 997 million total reads were generated for the five collies. Over
one billion total reads were generated for the Shetland sheepdog. Paired reads were
aligned to the indexed reference (CanFam3.1) with Bowtie2 [63] under sensitive
parameters. The alignments were sorted and indexed with SAMtools [64,65] to be
visualized in the Interactive Genomics Viewer [66].

RNA isolation and sequencing.
Total RNA was extracted from 30-40mg of skin punch biopsy tissue from active
lesions (collie and Shetland sheepdog) or healthy skin (Australian shepherd) using the
ToTALLY RNA kit (Ambion), according to the manufacturer’s protocols. RNA samples
were treated with DNase to remove DNA contamination, using the DNA-free kit
(Ambion). Samples were quantitated on a NanoDrop 1000 spectrophotometer (Fisher
Scientific).
Three RNAseq libraries were constructed per dog using normalized total RNA
and the manufacturer's protocol for one of the following: TruSeq RNA library prep kit
v2.0 (Illumina) or TruSeq stranded total RNA library prep kit (Illumina). An Agilent
Bioanalyzer 2100 was used for size validation. Each sample was sequenced at 2 x 125bp
paired-end on an Illimina HiSeq 2500 to a depth of at least 22 million reads.
FastQC from the Babraham Institute was used to assess read quality before and
after preprocessing by Trimmomatic [67], which removed low quality bases and
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remaining sequence adapters. Trimmed reads for each sample were aligned to
CanFam3.1 using gsnap [68], and SAMtools [64,65] was used to generate sorted and
indexed bam files.

Variant filtering and genotyping.
SAMtools and BCFtools [64,65] were used to generate variant call files for each
sample, which were analyzed in SVS. On chromosome 10 (1-1,333,693 bp) variants that
were heterozygous in affected collies 1 & 2 and homozygous in affected collie 3 and the
affected Shetland sheepdog (i.e., reference/reference or alternate/alternate), consistent
with the allele states at the lead SNPs, were selected. On chromosome 31 (24,026,41124,722,836 bp), all homozygous variants in the Shetland sheepdog were selected.
Ensembl 79 was used to identify variants lying within predicted exons and 10 bp flanking
sequences to capture splice sites. RNAseq data were manually inspected in IGV to
determine whether predicted exonic variants were expressed in the affected dogs.
Alternate variants were investigated using dbSNP and 27 genomes of 16 other breeds
(either sequenced as part of ongoing studies or shared by other research groups) to
determine whether any were unique to collies and Shetland sheepdogs. SIFT [31],
PolyPhen [32], and PANTHER [33] were used to predict the impact of the amino acid
substitutions. Genotyping of variants in additional dogs was accomplished by restriction
digest assays or Sanger sequencing (S6 Table).
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Age of onset.
Because age is not distributed as a normal random variable, we made use of the
Weibull distribution, a density commonly used for time-to-event data [69]. Our goal was
to estimate the mean and median age of onset, along with their confidence intervals, to
facilitate comparisons across the three genotypic groups.
Taking advantage of a Bayesian strategy, we assume yij ~ Weibull (r, 𝑒𝑒 −𝑏𝑏𝑖𝑖 ), where

yij is the observed age at diagnosis for the j-th (j = 1, 2, …, ni) dog in the i-th (i = 1,2,
…,3) genotypic class and bi is the effect of the i-th genotypic class. With this

representation of the scale (r) and shape (𝑒𝑒 −𝑏𝑏𝑖𝑖 ) parameters of the Weibull density, the
median of the i-th genotypic class is 𝑒𝑒 −𝑏𝑏𝑖𝑖 log(2)1/r and the mean of the i-th genotypic

class is 𝑒𝑒 −𝑏𝑏𝑖𝑖 Γ(1 + 1/r).

In addition, we assumed a prior density for the unknown genetic parameters (bi)

to have a null mean and common variance σ (i.e., (bi ~ N(0, σ)). We consider the weakly
informative prior for σ ~ Cauchy(0,25) [70]. For the scale parameter, r, we assume the
weakly informative prior of r ~ exponential(0.001). The Monte Carlo Markov Chain
(MCMC) sampling process was run in 4 chains through the public-domain software Stan
[71], with each chain based on 50,000 total samples, and the first 20,000 were removed
as part of the warm-up process, then thinned to every 20th sample, resulting in a MCMC
sample of 6,000 values [71]. Convergence to the posterior density was evaluated by the
Gelman-Rubin test statistic, where values less than 1.05 indicate that the MCMC
sampling process was adequate to the data evaluated [72].
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Genetic interaction analyses.
All affected (n=132) and healthy (n=390) dogs were used to investigate possible
interactions between the PAN2 variant encoding p.Arg492Cys and MAP3K7CL
c.383_392ACTCCACAAA>GACT in dogs homozygous for 002:01/009:01/001:01 vs.
dogs heterozygous for the haplotype. Three-locus genotypes observed in fewer than five
dogs were excluded. For a given disease state (cases vs. controls) and a given pair of
genotypic classes i (i = A/A, A/a, or a/a) and j (j = B/B, B/b, or b/b), ncases ij ~
Binomial(ncases ij + ncontrols ij , pij) where ncases ij is the number of observed cases in the
combination of the genotypic class of locus i and that of locus j, ncontrols ij is the number
of unaffected dogs in the combination of genotypic class of locus i and that of locus j.
Finally, pij is the probability of disease for the combined genotypic classes of i and j.
Estimation of the unknown elements of our model must ensure estimates of pij
within the interval [0,1], recognizing that several genotypic classes have zero or few
cases. We utilized a hierarchical Bayesian framework facilitated through the publicdomain software Stan [71] to address this problem [73]. Stan can be accessed through the
public-domain language R [74]. Log-odds was used to estimate pij, i.e., log(pij /(1- pij)) =
intercept + addAi + domAi+ addBj + domBj + add x addij + add x domij + dom x addij +
dom x domij, where intercept represents a term common to all genotypic classes, addAi,
addBj domAi and domBj represent the additive and dominance terms respectively for loci
A and B, and add x addij + add x domij + dom x addij + dom x domij represent the four
possible epistatic interaction terms for all possible additive and dominance combinations
[53].
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We assumed a prior density for the intercept and unknown genetic parameters,
with null mean and common variance σ (i.e., N(0, σ)). Subsequently, we consider the
weakly informative prior for σ ~ Cauchy(0,25) [70]. We used the same MCMC
parameters here as described above.

Chromosome 12 selective sweeps.
We identified all SNPs on chromosome 12 present in five collie genomes (3 cases
and 2 controls) and used a creeping window size ≤1 Mb to identify runs of homozygosity
[75]. Windows containing fewer than 50 SNPs were excluded and gaps >10kb between
SNPs were ignored. The heterozygosity (Hp) statistic was calculated for all windows and
Z-transformed, making the average Hp value equal to zero and the standard deviation
equal to 1. The –ZHp distribution was plotted in R to show putatively selected regions
greater than 3.4 standard deviations from the mean.

PMEL
D' between PMEL and PAN2 was calculated as a measure of LD using all dogs
for which coat pattern phenotypes were available (112 cases, 385 controls). A total of 98
dogs (10 cases and 88 controls) were described as merle-patterned, a semi-dominant trait
caused by the Merle (M) allele of PMEL, and assumed to possess the Mm genotype.
Computation of D', along with a test of significance from zero, was facilitated through
the package genetics [76], a public domain program that is part of the R language [74].
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Accession numbers
SNP data are available in dbSNP under BioProject number PRJNA338128. All
whole genome and transcriptome data generated for this study were deposited in SRA
genomes under accesssion number SRP081080. Accession numbers for eight of the 27
other breeds used in variant filtering are SRX1360633, SRX1360635, SRX1360637,
SRX1360639, SRX1022256, SRX1022262, SRX1022286, and SRP081080.
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CHAPTER FIVE
CONCLUSION
The outcome of this work was the identification of mutations underlying three
inherited diseases of dogs: nemaline rod myopathy in American bulldogs, limb girdle
muscular dystrophy in Boston terriers, and dermatomyositis in collies and Shetland
sheepdogs. Genetic tests are now available to facilitate breeding decisions and reduce the
risk of disease in the affected breeds.

Nemaline rod myopathy in American bulldogs
Genome-wide SNP and whole-exome resequencing (WES) data were generated
for a nuclear family of American bulldogs (ABDs) with two autosomal recessive cases of
nemaline rod myopathy. Candidate intervals were determined based on allele frequency
in the cases vs. the unaffected family members. SNP genotypes consistent with an
autosomal recessive inheritance pattern were identified proximal to NEB and TNNT1, two
known candidate genes. WES revealed a nonsense mutation in exon 176 of183 in NEB.
This variant was absent in unrelated ABDs as well as dogs of other breeds, indicating that
it is private to the family. A genetic test now exists for nemaline rod myopathy in ABDs,
and this work demonstrated the utility of WES in detecting autosomal recessive variants
when few cases are available for study.
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Limb girdle muscular dystrophy in Boston terriers
We identified independent mutations in SGCD causing limb girdle muscular
dystrophy (LGMD) in two unrelated Boston terriers. LGMD has been described
previously in dogs but never molecularly characterized until now. WES of the cases and
unaffected family members of one case revealed two SGCD deletions: a 2 bp deletion
segregating in the family and a 19.4 kb deletion encompassing exons 7 and 8 of SGCD in
the unrelated case. Given that LGMD is rare in dogs and that both affected dogs were of
the same breed, we expected to identify a single mutation present at a very low frequency
in the Boston terrier breed. This work again demonstrates the efficacy of WES for
identifying causative mutations of simple recessive disorders, particularly when candidate
genes are available. Should future cases of LGMD be identified in Boston terriers, a test
is now available for each of the identified mutations, and there is now potential for a
large animal model for LGMD2F gene therapy.

Dermatomyositis in collies and Shetland sheepdogs
Dermatomyositis (DMS) is a complex autoimmune disease with environmental
and genetic influences and is a model for human juvenile dermatomyositis (JDM). To
date, major associations with JDM have not been identified outside of the major
histocompatibility complex (MHC), although other risk factors of strong effect are
believed to exist. Investigation of the dog leukocyte antigen loci in affected and healthy
collies and Shetland sheepdogs revealed a haplotype overrepresented among affected
dogs (DLA-DRB1*002:01/-DQA1*009:01/-DQB1*001:01). Through a combination of
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genome-wide association studies (GWAS), whole genome resequencing (WGS), and
transcriptome sequencing, we identified strong associations with variants in two genes
never before implicated in disease, PAN2 and MAP3K7CL. Furthermore, we found
evidence for additive-by-additive epistasis between the novel risk loci.
None of the risk alleles were private to collies and Shetland sheepdogs, but these
breeds were unique in their high frequencies of risk alleles at the three loci. We
determined that linkage disequilibrium between the M allele of SILV and the wildtype
PAN2 allele has impeded elimination of the risk allele in the absence of a genetic test.
Furthermore, we found evidence for a selective sweep including the MHC on
chromosome 12 in collies, explaining their fixation for the DMS risk haplotype. It is
likely that breeders fixed this locus inadvertently while selecting for a desirable
phenotype. The presence of a second MHC haplotype in Shetland sheepdogs contributed
to the higher incidence of the MAP3K7CL variant in this breed.
This work is the first in dogs to identify disease risk associated with combinations
of polymorphisms across three independent loci, and we can explain 93% of cases with
these three-locus genotypes. It has also yielded novel genes for investigation in human
cases of dermatomyositis. Because DMS is fully penetrant in dogs homozygous for risk
alleles at all three loci develop DMS, there is potential to study changes to the immune
system prior to disease onset. Such research has not previously been possible and may
allow for the development of biomarkers for diagnosis of JDM before clinical symptoms
ensue.
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For dogs, this work has resulted in a genetic test that will allow breeders to
preserve genetic diversity, while reducing the incidence of the risk alleles in these breeds.
Prior to the development of a test, affected dogs and parents of affected dogs would be
culled from the breeding population. Now all dogs can be safely bred to produce puppies
with low-risk genotypes, and Shetland sheepdog breeders can maintain the second DLA
haplotype found in that breed.
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Association of DLA-DQB1 alleles with exocrine pancreatic insufficiency in Pembroke
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Summary
Exocrine pancreatic insufficiency is a digestive disorder resulting from
insufficient secretion of enzymes from the pancreas. In dogs, this condition is often
attributed to pancreatic acinar atrophy, wherein the enzyme-producing acinar cells are
believed to be destroyed through an autoimmune process. Although exocrine pancreatic
insufficiency affects many diverse breeds, to date, molecular studies have been limited to
the German shepherd dog. A recent study of major histocompatibility genes in diseased
and healthy German shepherd dogs identified both risk and protective haplotypes. Herein,
we genotyped DLA-DQB1 in Pembroke Welsh corgis to determine if dog leukocyte
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antigen alleles contribute to the pathogenesis of exocrine pancreatic insufficiency across
dog breeds. We evaluated 14 affected and 43 control Pembroke Welsh corgis, which
were selected based on an age of onset similar to German shepherd dogs. We identified
one protective allele (odds ratio=0.13, P-value=0.044) and one risk allele (odds ratio=3.8,
P-value=0.047). As in German shepherd dogs, the risk allele is a duplication of DLADQB1 (alleles DQB1*013:03 and 017:01); however, Pembroke Welsh corgis have
acquired a single polymorphism on DQB1*017:01. Thus, the DLA-DQB1 duplication is a
risk allele for exocrine pancreatic insufficiency in at least two breeds.

Exocrine pancreatic insufficiency (EPI) results from the failure of pancreatic
acinar cells to produce enough enzymes for proper digestion of macromolecular nutrients.
Clinical signs include increased appetite, weight loss, and loose stools. It has been
suggested that clinical signs occur when <10% of pancreatic enzyme reserves remain [1].
EPI is typically managed with supplemental enzymes. Veterinarians screen for EPI
through measurement of serum canine trypsin-like immunoreactivity (cTLI)
concentration; however, the underlying cause is usually undetermined. In dogs, EPI is
most commonly caused by pancreatic acinar atrophy (PAA), an autoimmune disorder
resulting from selective degradation of acinar cells after lymphocytic infiltration [2].
PAA is responsible for hereditary forms of EPI and has a complex mode of inheritance
[3].
EPI occurs across many dog breeds but is especially prevalent among German
shepherd dogs (GSDs). Tsai et al. [4] recently identified associations between EPI and

125

four-locus dog leukocyte antigen (DLA) haplotypes in GSDs. The DLA locus is part of
the canine major histocompatibility complex, a superlocus of genes involved in immune
function. The identified risk haplotype (DLA-88*045:02/DLA-DRB1*012:01/DLADQA1*004:01/DLA-DQB1*013:03+017:01; for nomenclature, see Kennedy et al. [5])
contains a DLA-DQB1 allele that is not found on other haplotypes. This allele is a
duplication composed of two alleles (DQB1*013:03 and 017:01) and has been reported
in at least 15 breeds [6], including several reported to have EPI. As in GSDs, Pembroke
Welsh corgis (PWCs) have a young average age of onset (~3 years), which may imply a
similar pathogenesis [7]. To determine whether DQB1*013:03+017:01 confers risk for
development of EPI in breeds besides GSDs, we genotyped DLA-DQB1 in diseased and
healthy PWCs.
Whole blood or buccal cells were obtained from PWCs across 22 states recruited
through www.epi4dogs.com and the Pembroke Welsh Corgi Club of America. All
samples and informed owner consent were collected according to protocols approved by
the Clemson University Institutional Review Board (IBC2008-17). Pedigree information
was obtained for 54% of participants. Among these, all dogs were unrelated at the
parental level with most unrelated through the grandparent level. All 14 PWC cases were
diagnosed based on clinical assessment by their private veterinarians and fasting serum
cTLI concentrations ≤2.5 µg/L (reference interval: 5.7-45 µg/L). PWC cases had an
average age at diagnosis of 2.9 years.
All 43 dogs selected as controls were ≥8 years of age (average=11 years),
exhibited no clinical signs of EPI or digestive disorders, and had no immediate family

126

members diagnosed with EPI to the owner’s knowledge. Although rare, subclinical cases
have been reported in GSDs [8]. Fasting serum samples were collected from six controls
having the DLA-DQB1 duplication and submitted to the Gastrointestinal Laboratory at
Texas A&M University for cTLI measurement. All dogs had cTLI concentrations within
the normal range.
The hypervariable regions of DLA-DQB1 and DLA-DRB1 were amplified from
genomic DNA using primers and thermal cycling parameters reported by Kennedy et al.
[6] or modified from Massey et al. [9] (Table S1). Products were purified according to
Massey et al. [9] and sequenced on an ABI 3730xl Genetic Analyzer (Life Technologies).
Results were compared with published nucleotide sequences to assign genotypes [10],
and statistical analyses were performed using VassarStats (Vassar College).
Gel extracted PCR product from a dog having a novel DLA-DQB1 allele was
subcloned into pGEM®-T Easy vector according to the manufacturer’s protocols
(Promega). Colonies containing the insert were selected, and the vector and insert were
sequenced.
In our cohort, we identified 11 DLA-DQB1 alleles, for which 96% of PWCs were
heterozygous (Table 1). The most commonly observed alleles were DQB1*020:02 and
001:01 (18% each), followed by 003:01 (16%).
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Cases

Controls

DLA-DQB1

OR

95% CI

P-value

30

2.3

0.67–7.9

0.21

13

30

0.38

0.075–1.97

0.31

21

15

35

0.51

0.12–2.1

0.51

0

0

1

2.3

008:02

1

7.1

16

37

013:02

0

0

1

2.3

-

013:03
013:03+
017:02
020:02

0

0

1

2.3

-

7

50

9

21

3.8

1.1–14

0.047

6

43

15

35

1.4

0.41–4.8

0.75

023:01

1

7.1

1

2.3

-

035:01

0

0

1

2.3

-

n=14

(%)

n=43

(%)

001:01

7

50

13

002:01

2

14

003:01

3

007:01

0.13

0.02–1.1

0.044

Table 1. Frequencies and statistical values for each DLA-DQB1 allele in PWC cases and
controls under a dominant model. Statistical values are shown for alleles present in more than two
PWCs and are calculated based on numbers of dogs with and without each allele. Significant values
are highlighted in bold font. OR=odds ratio, CI=confidence interval

We initially genotyped seven cases and nine controls as heterozygous for
DQB1*013:03+017:01. Eight of these were in combination with three alleles that did not
match reported alleles but most closely resembled DQB1*001:01, 003:01, and 035:01.
To better characterize these alleles, DLA-DRB1 genotypes were generated for five PWCs,
representing each of the three unknown alleles. All dogs were heterozygous for
DRB1*012:01, which is on a haplotype with DQB1*013:03+017:01 [11]. The alternate
alleles were DRB1*002:01, 015:01, or 025:01, which are reported on the same
haplotypes as DQB1*001:01, 003:01, and 035:01, respectively [11]. Further examination
of DQB1 sequence data from all dogs having the duplication revealed a shared mutation
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(c.236A>T) at a known polymorphic site. These data suggest that the mutation is present
on the common allele, DQB1*013:03+017:01, rather than on the alternative alleles.
Subcloning and sequencing of the DLA-DQB1 duplication revealed that the c.236A>T
mutation is found in DQB1*017:01; no changes were present in DQB1*013:03 (Figure
1A). The curator of the canine immunopolymorphism-MHC database termed the new
allele DLA-DQB1*017:02 and the duplicated allele present in PWCs DLADQB1*013:03+017:02.
We subsequently developed a method of distinguishing dogs having
DQB1*013:03+017:01 from those having DQB1*013:03+017:02 in direct sequences.
Initially, c.236A>T was only apparent when the DLA-DQB1 duplication was paired with
an allele having an A at this position (DQB1*001:01, 003:01, 023:01, and 035:01).
Chromatograms from this allelic combination have a stronger A signal resulting from a
2:1 ratio of As to Ts: one T from DQB1*017:02, one A from DQB1*013:03, and a
second A from the third allele (Figure 1B).
The remaining eight DQB1*013:03+017:01 alleles were paired with alleles
having c.236A>T (DQB1*002:01, 008:02, and 020:02). Chromatograms from these
allelic combinations showed a stronger T signal, suggesting a 1:2 ratio of As to Ts. In
chromatograms from GSDs having DQB1*013:03+017:01 and an allele with c.236A>T,
the A signal is greater (Figure 1B). Therefore, we determined that the remaining PWCs
have the DQB1*013:03+017:02 duplication, which is contributing the second T in the
1:2 ratio, and that no dogs in our cohort have DQB1*013:03+017:01.
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To determine if DLA-DQB1 alleles are associated with EPI in PWCs, a Fisher’s
exact test was conducted using numbers of dogs possessing a given allele. This approach
assumes a dominant model, wherein only one allele is necessary to increase risk.
DQB1*013:03+017:02 was determined to confer risk (OR=3.8, P-value=0.047). Another
allele, DQB1*001:01, had an odds ratio suggestive of risk (OR>2.0), but its P-value was
not significant (Table 1).
A single allele, DQB1*008:02, was significantly associated with PWC controls,
indicating protection. This allele was not observed in GSDs [4]. In GSDs, EPI-protective
DLA haplotypes included DQB1 alleles 002:01 and 003:01 [4]. In the PWCs, these
alleles had odds ratios suggestive of a protective effect (OR<0.5); however, the P-values
were not significant (Table 1).
In GSDs, the protective haplotype was dominant, such that the single dog having
both protective and risk haplotypes did not develop EPI [4]. In this study, we observed
two PWC controls that possessed both the risk and protective alleles. This genotype was
not observed among PWC cases, indicating that the protective allele may be dominant to
the risk allele. One case had DQB1*008:02 paired with a non-risk allele, suggesting that
the protective allele does not fully prevent risk for EPI.
The duplication of DQB1*013:03 and 017:01 occurs across several breeds and
represents an ancestral event. Genotyping of DLA-DRB1 showed that the PWC
duplication occurs with DRB1*012:01, as does DQB1*013:03+017:01. Taken together,
these data indicate that the duplication in PWCs is not a novel event. Rather, we suggest
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that PWCs have acquired a polymorphism on DQB1*017:01 within the duplication,
which has not yet been reported in other breeds.
In conclusion, we have identified both risk and protective alleles contributing to
EPI in PWCs. Our findings combined with those of Tsai et al. [4] show that this DLADQB1 duplication is associated with EPI in multiple dog breeds. Further studies are
necessary to determine if the duplication itself or a variant in linkage disequilibrium is
contributing to the pathogenesis of EPI.
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Reagents

Temperature

Time

Cycles

2X Reddy Mix
Sterile water
0.4 μM Primer
50 ng DNA

95°C
95°C
73°C
72°C
72°C

5 minutes
30 seconds
1 minute
1 minute
5 minutes

1

4°C

hold

hold

Total reaction
volume: 25 μL

30
1

S1 Table. Reagents and thermal cycling conditions for DLA-DQB1 amplification
are shown.
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Appendix B
Supplemental information for Chapter 3

Primer Set

F primer sequence

R primer sequence

Expected size (bp)

Purpose

Exon 6

CGCTGGCAAAAT

GGCAATCTCCT

420

Case 3 & 4

CCGTGCTTTGGG

CCTCCAGACCC

mutation

CC

genotyping

Exon 7

ACCTTCTGATTG

TTACTTCCTCCC

GCTCCTCT

TCATAAACTTG

CCACCCACACAC

TGCTCACTTAG

ATACACACA

GCTGAACACA

SGCD

GTGTCGAGGGTG

ATTAGGGAGGC

Case 1 mut

AAATAAGTGA

CAGTCTATTCA

Exon 8

427

Not present in
Case 1

441

Not present in
Case 1

678

Case 1
mutation
genotyping

SGCD

CACATTATGGAG

CCATCACTAAA

434

Case 1

Case 1 wt

TCTGAGCTAACT

TAGTCTCAGCT

mutation

GT

genotyping

Case 1

GGCTTCATAGAT

ATTTCCATCTCA

Wt = 20681 (no

Case 1

breakpoint

AGTGGGCTG

AACTCATTCAA

amplification)

breakpoint

Case 1 affected:

determination

1275

S1 Table. Primers used to define and genotype SGCD mutations.
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Appendix C
Supplemental information for Chapter 4

S1 Figure. Clinical presentation of dermatomyositis. Canine dermatomyositis is a vasculopathy
that initially manifests as cutaneous lesions across the bony prominences of the face, tail tip, limbs,
and feet, shown here. Some dogs develop alopecia and more extensive lesions over time, resulting in
dermal scarring associated with erythema and mottled pigmentation.
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S2 Figure. Manhattan and quantile-quantile plots of combined DMS GWAS (97 cases vs. 68
controls). The -log10P-values (y-axis) for 98,520 Illumina SNPs are plotted against chromosome
position (x-axis). The threshold for Bonferroni significance is shown as a black horizontal line. The
P-value and position (canFam3) of the lead SNPs are reported. The Q-Q plot is boxed in purple and
plots observed vs. expected Fisher’s exact -log10P-values. The inflation factor (λ) is shown on the QQ plot.
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S3 Figure. MAP3K7CL indel with conservation and RUNX3 binding motif. UCSC 100
Vertebrates track for human chr21:29,130,846-29,130,860 showing the G insertion and seven base
pair deletion created by MAP3K7CL indel (Dog c.383_392ACTCCACAAA>GACT). Bases in gray
differ from the dog reference sequence. The canine sequence is highlighted in yellow. The RUNX3
binding motif is underlined.
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S4 Figure. Three-locus genotype disease probabilities by sex. Probability of disease (y-axis) for all
combinations of PAN2 (x-axis) and MAP3K7CL genotypes are plotted in dogs (73 affected and 145
unaffected males; 59 affected and 245 unaffected females) (top) homozygous and (bottom)
heterozygous for DLA-DRB1*002:01.
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S5 Figure. Median age of onset for combinations of PAN2 and MAP3K7CL genotypes. Median
age of onset is plotted for genotypes consisting of 2 (AAbb, aaBB, AaBb), 3 (AABb, AaBB), and 4
(AABB) risk alleles at PAN2 and MAP3K7CL. CC and Cc genotypes were combined for analyses.
Number of individuals is shown to right.
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S6 Figure. Collie selective sweeps on chromosome 12. ZH(p) values for all creeping windows
containing 50 or more SNPs are plotted against chromosome position. Creeping windows are ≤1 Mb.
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S1 Table. SNPs exceeding Bonferroni significance (5.08X10-7).
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143

144

145

146

147

148

149

150
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S2 Table. Chromosome 10 variants segregating with the lead SNPs in the affected dogs.
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S3 Table. Chromosome 31 variants segregating with the lead SNPs in the affected Shetland
sheepdog. The first page of the table is shown; the remaining 92 pages can be found at
http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006604#sec021
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S4 Table. Frequency of PAN2 and MAP3K7CL genotypes.
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157

158
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S5 Table. Three-locus genotypes for 229 individuals of 30 breeds.
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S6 Table. Primers and genotyping method for variants.
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